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1 INTRODUCTION 
1.1 Bladder cancer 
1.1.1 Epidemiology 
Bladder cancer (BLCA) is the tenth most common cancer worldwide with 
estimated 550,000 new cases and 200,000 deaths in 2018 [1]. BLCA is more 
common in men than in women. The incidence of BLCA rises with age, peaking 
between age 50 years and 70 years. With mean age for male patients of 69 
and female patients of 73.4, men are three to four times suffered as women, 
while the latter suffered from more aggressive forms of BLCA [1]. Incidence 
rates in both sexes are highest in Southern Europe (Greece with the highest 
incidence rate in men globally), Western Europe and Northern America (Figure 
1). 
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Figure 1. Bar Chart of Region-Specific Incidence Age-Standardized Rates by Sex for 
Cancers of the Bladder in 2018. Rates are shown in descending order of the world (W) age-
standardized rate among men, and the highest national rates among men and women are 
superimposed. Source: GLOBOCAN 2018. 
 
1.1.2 Risk factors and classification 
The main risk factors of the occurrence of BLCA include cigarette consumption 
and industrially produced chemicals, as well as genetic and molecular 
abnormalities [2, 3]. Genetic and molecular factors include oncogenes and 
tumor suppressor genes. It is reported that oncogenes such as tumor protein 
p63 (TP63), the epidermal growth factor receptors (EGFR), and Ras p21 
proteins [4-6] are involved with carcinogenesis and progression of BLCA. 
Furthermore, tumor suppressor genes probably play a part in the genetic 
pathogenesis of BLCA, including tumor protein p53 (TP53) and retinoblastoma 
gene (RB1) [7, 8].  
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Two main different types of BLCA can be distinguished: non-muscle invasive 
BLCA with low-grade and muscle invasive cancer with high-grade tumors and 
high risk of metastasis in regional lymph nodes, lungs, liver and bone [9]. Non-
muscle-invasive BLCA (NMIBC; 70%) is not immediately life threatening but 
often progress, while muscle-invasive BLCA (MIBC; 30%) is responsible for the 
most cases of metastases and death [10]. The classification of tumors is based 
on the Tumor-Node-Metastasis (TNM) classification of the Union for 
International Cancer Control (UICC) of 2010, accordingly include papillary 
tumors (Ta) and the non-invasive urothelial carcinoma, which infiltrate the 
subepithelial connective tissue (T1). T2 to T4 are tumors that invade the muscle, 
the fat tissue and / or surrounding tissue with different depths and counted as 
the invasive carcinomas [11]. The existing clinical staging and pathological 
grading of BLCA are depending on observation by naked eye and microscopy. 
It cannot comprehensively and accurately assess the biological activities of 
tumor cells, such as proliferation ability, development and invasiveness. 
Therefore, in-depth research, which clarifies the biological process of BLCA and 
the molecular regulatory network, can improve early diagnosis, treatment 
effects, and prognosis. 
Currently, several classifications have proposed into sets of molecular classes, 
including basal and luminal subtype, which partially characterized by KRT5 and 
KRT20 gene expression [12]. Although a number of groups have reported 
molecular classifications of BLCA to evaluate the severity and prognosis of this 
disease, reliable and effective biomarkers for early diagnosis and prognostic 
prediction are still lacking [13, 14]. Thus, in-depth understanding of molecular 
events and underlying mechanisms involved in the carcinogenesis of MIBC 
may provide us effective therapeutic targets and predictive biomarkers, which 
are urgently needed. 
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1.1.3 Diagnostic and therapy 
Painless macrohematuria is the most common symptom of BLCA. Other typical 
symptoms are dysuria, increased urinary frequency or frequent urination 
urgency. However, the positive predictive value of hematuria for BLCA is only 
8% [15]. Although cystoscopy is an effective method for detecting BLCA, it also 
produces many adverse reactions. Common adverse reactions include 
infection, difficulty urinating, frequent urination, and hematuria [16]. Therefore, 
it is particularly important to study the mechanism of BLCA occurrence and 
development and control the recurrence of BLCA. It is necessary to develop 
non-invasive diagnostic tools for screening and monitoring of BLCA to improve 
the life quality of patients. For muscle-invasive non-metastatic urothelial 
carcinoma, radical cystectomy (RC) including bilateral pelvic lymphadenectomy 
is the curative treatment method of choice [17]. The current therapeutic 
standard for MIBC is RC with perioperative platinum-based chemotherapy in 
selected cases [18]. However, the postoperative recurrence rate is very high, 
and the 5-year recurrence rate can reach 50%-70%. The malignant degree and 
pathological grade of the tumor are significantly increased when some patients 
relapse [19]. 
 
1.1.4 Novel biomarkers of BLCA 
Limits in classification and high recurrence rate lead to the search for novel 
prognostic biomarkers. In recent years, the increasing number of basic 
researches on BLCA has shifted the research target from protein molecules to 
tumor-related genes and their regulatory factors. Different classes of 
biomarkers were proposed, including coding genes and non-coding genes.  
The coding gene anilin actin binding protein (ANLN) is located on chromosome 
7q14.2 and encodes for a 1,125 amino acid actin-binding protein that includes 
a conserved N-terminal actin (F-actin) and myosin binding region and a 
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conserved C-terminal pH binding domain [20]. Previous studies found that 
ANLN expression levels were significantly up-regulated in a variety of tumor 
tissues, including breast, ovarian, colon, lung, and pancreatic cancers [21-26]. 
Furthermore, ANLN and its encoded protein are highly expressed in BLCA 
tissues, and their expression levels are positively correlated with the 
pathological grade and stage of BLCA [27]. However, the involved signaling 
pathways and the interacting molecular targets in the regulation of BLCA 
biological function are in discussion.  
Transducing-like enhancer protein 2 (TLE2), a member of the TLE gene family, 
is located on chromosome 19p13.3, and acts as a transcriptional corepressor 
[28]. Previous studies revealed that the molecular properties of the TLE2 
protein point to a function in transcriptional regulation, involved in embryonic 
neuronal development in conjunction with Hairy/Enhancer of split (HES) 
proteins [28, 29]. The TLE2 protein inhibits replication-and-transcription-
activator-mediated transactivation and lytic reactivation of Kaposi’s sarcoma-
associated herpesvirus [30]. The function of TLE2 in BLCA has not yet been 
investigated. 
The Wnt/β-catenin pathway was reported to be required for regeneration of the 
normal urothelium [31]. Also, previous studies have indirectly suggested the 
involvement of Wnt/β-catenin pathway in malignant behavior of BLCA cells [32, 
33]. However, the involved molecules and mechanism of Wnt/β-catenin 
pathway in MIBC are still unclear. In a previous study, ANLN expression was 
associated with Wnt/β-catenin signaling in gastric cancer [34]. Also, the Wnt/β-
catenin pathway regulates gene expression via T-cell factor/lymphoid 
enhancer-binding factor 1 (TCF/LEF1) family, which is repressed by 
transcription factors for TLEs [35, 36]. However, the association between ANLN 
and TLE2, as well as the association with BLCA was not elucidated yet. Thus, 
ANLN and TLE2 were chosen as candidates in this study. 
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1.2 Long noncoding RNA 
1.2.1 Characteristics of long non-coding RNA 
Long non-coding RNAs (lncRNA) are a class of RNAs that are more than 200 
nucleotides in length and lack the ability to encode proteins [37, 38]. In the past, 
lncRNAs have been considered to be "noise" during transcription process, 
which do not have any biological function. LncRNA has several structural and 
expressional characteristics, suggesting that it is not a transcription "noise", but 
an important functional RNA: 1) lncRNA mostly has an mRNA-like structure with 
a promoter region and polyA tail and there are different ways of cutting during 
maturation [39]; 2) most lncRNA expressions are spatiotemporal specific [40]; 
3) many lncRNAs display abnormal expression patterns in diseases [41]. 
Existing research shows that lncRNA, as an important form of epigenetics, 
plays a regulatory role at multiple levels within the cell (Figure 2).  
 
 
Figure 2. Characteristics of lncRNAs. The genomic location, RNA features and other 
characteristics of lncRNAs were illustrated. The majority of lncRNA genes are located within 10 
kb of protein-coding genes and many lncRNAs are antisense to coding genes or intronic. Many 
lncRNA genes have two or more exons and about 60% of lncRNAs have polyA+ tails. Other 
characteristics are involved in the functions of lncRNAs, including subcellular localization, 
stability, conservation and tissue specificity. 
 
For example, it interferes with the expression of neighboring coding genes; 
mediates chromatin remodeling and histone modification; forms a 
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complementary double-strand with the transcript of the coding protein gene, 
interferes with mRNA shearing; and binds to specific proteins to change the 
intracellular localization of the protein [42, 43]. Different positions of lncRNAs 
may exert their gene regulation through the mechanism of reversion. Antisense 
lncRNA often exhibits positive or negative correlation in expression with its 
neighboring mRNA, and may achieve multiple transcription and post-
transcriptional regulation of coding genes through complementary binding [44]. 
Intron lncRNAs may alter the transcript cleavage of neighboring coding proteins 
or enhance their stability [45]. The intergenic lncRNA has been shown to form 
a complex with the chromatin regulatory protein PRC2 and silence specific 
gene expression [46]. Although these RNAs are not translated into proteins, in 
fact, they interact with other molecules such as mRNA to form a complex 
network, which has many important biological functions and links in the human 
cells, especially tumors. 
1.2.2 LncRNA in cancer 
The occurrence and progression of tumors is a complex process involving 
multiple genes and multiple factors, as well as multiple biological interactions 
[47, 48]. Most of the basic research in the past decade has focused on detecting 
BLCA from protein-encoding genes. Related diagnostic markers and in-depth 
exploration of its role in the pathogenesis of BLCA are urgently needed.  
With continuous in-depth research on lncRNA, it is found that lncRNA widely 
participates in and constitutes the complex regulatory network of gene 
expression, epigenetic, transcriptional process, post-transcriptional 
modification, translation process and other levels to regulate gene expression, 
which ultimately achieve the purpose of playing an important role in 
tumorigenesis and development [49, 50]. Hepatic cancer, lung cancer, BLCA, 
breast cancer, pancreatic cancer, glioma, gastric cancer and many other 
malignancies have been confirmed to have abnormal expression of lncRNA [51-
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53]. For example, a study has found that the expression of HOTAIR in primary 
and metastatic breast cancer is significantly up-regulated. It can enhance the 
invasion of breast cancer cells by binding to the PRC2 protein, which affects 
epithelial-mesenchymal transition. And its expression level is related to breast 
cancer metastasis and prognosis [54]. Lu et al. and Miyoshi et al. reported that 
lncRNA MEG3 can be used as a tumor suppressor to regulate the occurrence 
and development of lung cancer and gliomas [55, 56]. It is also found that GAS5 
expression was significantly down-regulated in pancreatic cancer tissues, 
causing the proportion of cells in G0 / G1 phase decreased and the proportion 
of cells in phase S increased, and GAS5 overexpression could inhibit cell 
proliferation [57]. Shi et al. confirmed that GAS5 was lowly expressed in non-
small cell lung cancer tissues, and regulates the expression of P53 protein and 
the transcription factor E2F1 by inhibiting cell growth and aggravating apoptosis 
[58]. 
 
1.2.3 LncRNA in BLCA 
In recent years, many studies about the expression profile of lncRNAs in BLCA 
tissues have been emerged, as well as in-depth reports on the regulation of the 
proliferation and invasion of BLCA cells by specific lncRNA. Currently reported 
lncRNAs associated with BLCA include H19, UCA1, GAS5, MALAT1, MEG3, 
TUG1, HOTAIR, ucRAN, etc [59-64]. Luo et al. found that H19 plays a role in 
BLCA in the form of oncogenes. After the expression of H19 is up-regulated, it 
is combined with EZH2 to suppress the expression of E-cadherin and 
eventually promote the distant metastasis of BLCA cells [65]. The results of 
Zang et al. suggest that the key proteins in the UCA1 and PI3K / AKT signaling 
pathways have consistent expression trends, suggesting that UCA1 affects the 
expression level of the transcription factor CREB under the mediation of this 
pathway, which in turn affects the proliferation and the cell cycle is significantly 
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regulated [66]. Another study found that down-regulating GAS5 expression in 
BLCA tissues or cells, and inhibiting GAS5 can promote the proliferation of 
BLCA cells by regulating cyclin-dependent kinase 6 (CDK6) cyclin [63]. 
It is known that lncRNA is closely related to the occurrence, development, 
invasion and metastasis of BLCA [59]. Therefore, by screening differentially 
expressed lncRNA in BLCA, studying its effect on the biological function of 
tumor cells, and further revealing its specific mechanism for regulating the 
occurrence of BLCA, it is expected to open a new world for the diagnosis and 
treatment of BLCA.  
 
1.2.4 LncRNA MIR31HG in cancer 
Recently, miR-31 host gene (MIR31HG, Accession number: NR_027054, also 
known as LOC554202) has been identified implicated in several cancers, such 
as breast, colorectal, gastric cancer and pancreatic ductal adenocarcinoma [67-
70]. In breast cancer and non-small cell lung cancer (NSCLC) cells, MIR31HG 
expression was upregulated [67, 71]. While in gastric cancer tissues and cell 
lines, MIR31HG was poorly expressed [69]. It is also reported that MIR31HG 
expression was down-regulated in BLCA cell lines and tumor tissues [72]. 
However, the functional role of MIR31HG in proliferation and migration of BLCA 
cell lines, and the association with molecular classifications in BLCA is still 
unknown. 
 
1.3 Aims of this study 
Diagnostic and risk stratification of MIBC has barely changed over the last 
decades. Limitations in histopathological and molecular classification might 
lead to inadequate treatment decisions and result in high recurrence rates of 
MIBC. Besides, the expression and function of coding genes ANLN, TLE2 and 
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non-coding gene MIR31HG in MIBC are remain unknown. Therefore, the aim 
of the study was the analysis of gene expression and function of ANLN and 
TLE2, and lncRNA MIR31HG in BLCA cells and tissues.  
 
Therefore, the following questions were addressed in this work: 
- How is the gene expression of ANLN and TLE2, and lncRNA MIR31HG 
in MIBC? 
- How are the genes associated with the clinical and histopathological 
parameters?   
- Do the genes have a prognostic role and how is the association with 
survival of patients after RC? 
- How are the genes effects on proliferation and migration of BLCA cells? 
- How are the genes involved with signaling pathways and molecular 
subtypes of MIBC? 
 
To explore the correlation with histopathology and survival data of BLCA 
patients, expression of ANLN and TLE2 were investigated in our cohort by qRT-
PCR and validated in published datasets. For further revealing the potential 
mechanism, the involved signaling pathways and the impact of ANLN and TLE2 
on MIBC molecular subtypes were also evaluated. In addition, expression of 
MIR31HG and its splicing variants were explored in BLCA cell lines and 
correlated to survival in MIBC cohort. For functional analysis, knockdown of 
MIR31HG and a series of in vitro experiments were performed to investigate 
the effects of MIR31HG on proliferation, colony formation and migration of 
BLCA cells. Transcript-specific knockdown were carried out to reveal if 
MIR31HG and its splicing variants could associate with molecular subtypes. 
Further survival analysis in our cohort and validation in published datasets were 
performed to show if MIR31HG and its splicing variants could act as prognostic 
biomarkers. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Patients and tissue samples 
This study retrospectively enrolled 107 patients who received RC at the 
Department of Urology and Urosurgery of the University Medical Centre 
Mannheim, between 2008 and 2012, and who had a histological diagnosis of 
MIBC (males: n = 79, 74%, median age: 71 years, range: 41–88 years; females: 
n = 28, 26%, median age: 73 years, range: 47–86 years; Mannheim cohort). All 
patients were treated with RC and bilateral lymphadenectomy without 
preoperative or adjuvant chemotherapy or radiotherapy. With the help of the 
clinic’s internal documentation program, the following parameters were 
collected after examination of the pathology findings: sex, age, T-stage, N-stage, 
M-stage, grading, lymphovascular invasion (LVI), blood vessel invasion (VI), 
simultaneous carcinoma in situ (CIS), multifocality, and soft tissue positive 
surgical margin. 
Formalin fixed paraffin embedded (FFPE) tumor tissue samples were evaluated 
for pathological stage according to the 2017 TNM classification from the Union 
for International Cancer Control (UICC) [73]. Tumors were graded using the 
2017 WHO/ISUP classification (Table 1) [74]. Studies involving human 
participants were approved by the ethical board of the University of Heidelberg 
(2015-549N-MA) and performed in accordance with relevant guidelines and 
regulations. The Cancer Genome Atlas cohort (TCGA, Provisional) contained 
RNA sequencing data of 407 patients with MIBC and complete 
clinicopathological and follow-up data (males: n = 300, 73.7%, median age: 68 
years, range: 34–90 years; females: n = 107, 26.3%, median age: 72 years, 
range: 43–90 years; TCGA cohort). In the published TCGA dataset, patients 
with MIBC were classified into five molecular subtypes according to mRNA 
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clustering, including basal/squamous, luminal, luminal-infiltrated, luminal-
papillary and neuronal subtypes. In a previous study of our group, an alternative 
classification based on quantification of a 36-gene panel, clustered into 3 
subtypes (luminal, basal, infiltrated [p53-like]) on a cohort with MIBC, which also 
validated by the TCGA cohort [75]. 
 
Table 1. Clinicopathological characteristics of patients and 
specimens of this study. 
Clinicopathological Features n  % 
Age 
<70 46 43.0 
≥70 61 57.0 
Gender 
Male 79 73.8 
Female 28 26.2 
Grade 
Low 5 4.7 
High 102 95.3 
Stage 
I 5 4.7 
II 12 11.2 
III 69 64.5 
IV 21 19.6 
Lymph node 
metastasis 
Negative 75 70.1 
Positive 
Undefined 
24 22.4 
8 7.5 
Note: Stage I tumor was diagnosed as MIBC by transurethral resection of 
bladder tumor (TURBT). 
2.1.2 Database 
Expression data in transcripts per million (TPM) of 25 human BLCA cell lines 
were collected from the Cancer Cell Line Encyclopedia (Novartis/Broad, Nature 
2012) [76], including 20 bladder urothelial cell carcinomas, one bladder 
squamous cell carcinoma, and four bladder carcinoma cell lines from unknown 
primaries. Expression of ANLN, TLE2 and MIR31HG was analyzed by 
Expression Atlas (https://www.ebi.ac.uk/gxa/home) and normalized by TPM. 
Transcript expression data of 407 BLCA samples and 21 normal samples were 
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collected from TCGA (https://tcga-data.nci.nih.gov/tcga/) and analyzed by 
cBioPortal (http://www.cbioportal.org/), which normalized the samples by reads 
per kilobase million (RPKM). The height of a bar in the resulting bar plots 
represents the median expression tumor types or normal tissue. Each dot 
represents the expression of genes in samples in the dot-box plots. The protein-
protein interactions were analyzed by STRING (https://string-db.org/). The 
RNA-protein interactions were analyzed by lncPro 
(http://bioinfo.bjmu.edu.cn/lncpro/) [77]. GO enrichment analysis and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed by 
Enrichr (http://amp.pharm.mssm.edu/Enrichr/) [78]. Expression of transcripts, 
exons and junctions (log2 transformation) was collected and analyzed using the 
Xena online exploration tool (https://xena.ucsc.edu/) and TSVdb 
(http://www.tsvdb.com) [79]. 
 
2.1.3 Cell lines and cell culture material 
In this study six different cell lines were used, including a normal human 
urothelium cell line (UROtsa), a basal-like urothelial carcinoma cell line 
(SCaBER), two luminal-like urothelial carcinoma cell lines (RT112 and RT4), 
and two mixed-type urothelial carcinoma cell lines (UMUC3 and T24). UROtsa 
cell line was from the left ureter of a 12 year-old girl and immortalized by 
transfection with a temperature sensitive SV-40 large T antigen gene [80]. RT4 
cells established from a recurrent well-differentiated transitional papillary tumor 
of the urinary bladder of a 63-year-old man in 1968 [81]. RT-112 cells were from 
an unknown-aged woman with untreated primary urinary bladder carcinoma 
[82]. UMUC3 cells from an unknown-aged man with untreated primary urinary 
bladder carcinoma [83]. T24 cells established from the primary tumor of an 81-
year-old Caucasian woman with urinary bladder carcinoma in 1970, which 
described in the literature to produce a variety of cytokines (e.g. G-CSF, IL-6 
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and SCF) and to carry a p53 mutation [84]. SCaBER cells derived from a 58-
year-old male patient, described as squamous cell carcinoma of the human 
urinary bladder [85]. 
UROtsa cells were cultured in Roswell Park Memorial Institute medium (RPMI) 
supplemented with 5% fetal bovine serum (FBS). RT112, RT4, SCaBER, and 
UMUC3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% FBS. T24 cells were cultured in McCoy’s 5A medium containing 
10% FBS. UMUC3, SCaBER, RT112, and T24 cells were obtained from the 
European Collection of Authenticated Cell Cultures (ECACC), RT4 from the 
American Type Culture Collection (ATCC), and UROtsa cells from a 
collaborator. Before starting the experiments, all cell lines were authenticated 
by Multiplexion (Heidelberg, Germany).  
 
2.1.4 Chemicals and reagents 
The reagents and kits used in this study as well as their manufacturer and order 
number are showed in Table 2. The chemicals used in this study are listed in 
Table 3. 
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Table 2. Reagents and kits used in this study. 
Name Manufacturer 
Order 
number 
Cell Titer 96® Aqueous One 
Solution Cell Proliferation Assay 
Promega (USA) G3582 
Custom siRNA, Standard 0.015 
μmol Regular 
GE Healthcare (USA) 
SO-
2799195G 
DharmaFECT ™ Transfection 1 
Reagent 
GE Healthcare (USA) T-2001-03 
Fast SYBR Green Master Mix 
Life Technologies 
(USA) 
4385612 
Fetal bovine serum (FBS) Sigma-Aldrich (USA) F7524 
Lincode Set of 4 Upgrade siRNA, 
MIR31HG 
GE Healthcare (USA) 
SO-
2611084G 
McCoy's 5A (Modified) Medium Invitrogen (USA) 16600-082 
M-MLV Reverse Transcriptase Invitrogen (USA) 28025-013 
pdN6 random primer Roche (Germany) 
1103473100
1 
Protease Inhibitor Cocktails Sigma-Aldrich (USA) P2714 
RNase Away® 
Molecular 
BioProducts (USA) 
7003 
RNase OUT ™ Invitrogen (USA) 10777-019 
RPMI 1640 medium Invitrogen (USA) 21875-091 
Silencer® Select Negative Control 
siRNA 
Ambion (USA) 4390846 
Superscript® III Reverse 
Transcriptase 
Invitrogen (USA) 12574035 
TaqMan® Fast Advanced PCR 
Master Mix 
Life Technologies 
(USA) 
4444557 
RNeasy Mini Kit QIAGEN (Germany) 74104 
XTRAKT FFPE Kit Stratifyer (Germany) XTK2.0-96 
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Table 3. Chemicals used in this study. 
Name Manufacturer 
Order 
number 
Agarose 
Carl Roth 
(Germany) 
3810.3 
Crystal violet Sigma-Aldrich (USA) C0775 
DMEM, high glucose Invitrogen (USA) 41965-062 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (USA) D2650 
DPBS Invitrogen (USA) 14190 
Ethanol 100% 
Carl Roth 
(Germany) 
9065.1 
Glycine Sigma-Aldrich (USA) G8898 
Isotonic sodium chloride solution 
DeltaSelect 
(Germany) 
7462991 
Methanol 
Carl Roth 
(Germany) 
8388 
Nuclease-free water Promega (USA) p1193 
Trypan 0.4% Invitrogen (USA) 15250-061 
Trypsin-EDTA 0.25% Invitrogen (USA) 25200-056 
 
2.1.5 Devices and equipments 
The devices and equipments used in this study and their manufacturer are 
showed in Table 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
19 
 
 
 
Table 4. Devices and equipments used in this study. 
Name Manufacturer 
Accurate scales 
TSE Systems 
(Germany) 
Culture Insert 2 Well ibidi (Germany) 
Centrifuge 5804 Eppendorf (Germany) 
Centrifuge Rotina 430R Hettich (Germany) 
CO2 incubator BINDER (Germany) 
FlexCycler2 
Analytik Jena 
(Germany) 
Fridge freezer Grand Prix Bosch (Germany) 
Fridge freezer No frost Siemens (Germany) 
Herasafe ™ KSP Class II Biological 
Safety Cabinet 
Thermo Fisher 
Scientific (USA) 
Infinite® F200 PRO microplate reader TECAN (Switzerland) 
Inverted microscope Axiovert 10 Zeiss (Germany) 
LUNA cell counter 
Logos Biosystems 
(South Korea) 
Magnetic stirrer RCT basic IKA (Germany) 
Manual Rotary Microtome Leica (Germany) 
Milli-Q Synthesis Water Purification 
System 
Millipore (USA) 
Minishaker MS1 IKA (Germany) 
MiniSpin Eppendorf (Germany) 
NanoDrop 1000 Spectrophotometer 
Thermo Fisher 
Scientific (USA) 
Pipetus® pipette filler 
Hirschmann 
(Germany) 
Reax Top Vortex Mixer Heidolph (Germany) 
Sprout mini centrifuge Biozym Biozym 
StepOnePlus ™ Real-Time PCR 
System 
Applied Biosystems 
(USA) 
Water bath GFL (Germany) 
 
2.1.6 Small interfering RNAs 
Here, a pool of four different small interfering RNAs (siRNAs) against MIR31HG 
(designated si-MIR31HG, set of 4), and transcript-specific siRNAs against 
MIR31HGΔE1 and MIR31HGΔE3 were transfected into urothelial cells using 
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the DharmaFECT1 siRNA transfection reagent (GE Healthcare Dharmacon, 
Inc., CO, USA). Scrambled siRNA was used as negative control. All sequences 
of the siRNAs are listed in Table 5. 
 
Table 5. siRNAs used in this study. 
Target gene Sequence (5' → 3') 
MIR31HG 
GUUGAUGGUUAUUAGUGAA 
GCGCUUUGUGUGAGAAGUU 
AGGUUAUAUCCUAGAGAUC 
CAUAGAACCUUGGAUCCUA 
MIR31HGΔE1 CCCAGGAGGAGCUUGGUUUCUGGUU 
MIR31HGΔE3 GAGGAUUCAUUCCAAGGUAGAGAUU 
 
2.1.7 Primers and probes 
The sequences of primers and probes, which used in this study are listed in 
Table 6 and Table 7. 
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Table 6. Primers used in this study. 
Gene 
Forward primer sequence (5' 
→ 3') 
Reverse primer sequence (5' 
→ 3') 
ANLN GCATTAGCAGAAAGCAGC
GA 
TGGACACTAAACTCTCTGGA
CT 
Calm2 GAGCGAGCTGAGTGGTT
GTG 
AGTCAGTTGGTCAGCCATG
CT 
CDK1 AAAACTACAGGTCAAGTG
GTAGCCAT 
GCATAAGCACATCCTGAAG
ACTGACT 
COBL TACGCGTGGGACAACAG
AAG 
GGTCGTTAAACAGCCCTTAC
T 
CTNNB1 GGGTCCTCTGTGAACTTG
CTC 
TTCTTGTAATCTTGTGGCTT
GTCC 
EGFR CGCAAGTGTAAGAAGTGC
GAA 
CGTAGCATTTATGGAGAGT
GAGTCT 
FOXM1 GACCACCTGGAGCCCTTT
G 
GATGTTGGATAGGCTATTGT
TGATAGTG 
GATA3 GCAATGCCTGTGGGCTCT
AC 
TTCTGGTCTGGATGCCTTCC
T 
GUS GAAAATAYRTGGTTGGAG
AGCTCATT 
CCGAGTGAAGATCCCCTTTT
TA 
KRT5 CGCCACTTACCGCAAGCT ACAGAGATGTTGACTGGTC
CAACTC 
KRT20 GCGACTACAGTGCATATT
ACAGACAA 
CACACCGAGCATTTTGCAGT
T 
MIR31HG CTCTGGAGGACAGAGGA
TTCATTCC 
TGGGAGGGTGGTCTGAAAC
TG 
MIR31HGΔE1 GCCTCCCAGGAGGAGC CCAAACTCTGGAGGACAGA
GGATTC 
MIR31HGΔE3 CTCTGGAGGACAGAGGA
TTCATTCC 
GGAACACCTGGAGACCTGC
T 
MKI67 TGCTACTCCAAAGAAGCC
TGTG 
GTATGAGCTTTCCCTATTAT
TATGGTAC 
RacGap1 GAATGTGCGGAATCTGTT
TGAG 
TCGCCAACTGGATAAATTGG
A 
TLE2 AAGCGTCTGAGCGGTATC
TG 
TGCTGCTGCCCGATGAG 
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Table 7. Probes used in this study. 
Gene 5' Label 3' Label Sequence (5' → 3') 
ANLN FAM BHQ1 GAACAGGAAGATGCACTGAATAT
CTCCTCAATGTCTTTA 
Calm2 VIC BHQ1 TCGCGTCTCGGAAACCGGTAGC 
CDK1 FAM BHQ1 TCAGACTAGAAAGTGAAGAGGAA
GGGGTTCCTAGTACTG 
CTNNB1 FAM BHQ1 ACAAGGAAGCTGCAGAAGCTATT
GAAGCTGAGG 
FOXM1 FAM BHQ1 CGAGCAGAAACGGGAGACCTGTG
ATGGTGAGG 
GATA3 FAM BBQ ACAAGCTTCACAATATTAACAGAC
CCCTGACTATGAAG 
GUS VIC BHQ1 CCAGCACTCTCGTCGGTGACTGT
TCA 
KRT5 FAM BBQ TGGAGGGCGAGGAATGCAGACTC
A 
KRT20 FAM BBQ TTGAAGAGCTGCGAAGTCAGATT
AAGGATGCT 
MIR31HG FAM BHQ1 GGGTCTGCTTGTATTCAATGACTG
GTCTACGTGGG 
MIR31HGΔE1 FAM BHQ1 CAGGTTTCTGGTCCTCATACCGT
GTGGT 
MIR31HGΔE3 FAM BHQ1 GGTAGAGATGGATTCCTGGAAAT
ACCTCCTCAAGGCC 
MKI67 FAM TAM CGAAGTTCACAGTCAATTTAGTAC
AGGCCAC 
RacGap1 FAM BHQ2 ACTGAGAATCTCCACCCGGCGCA 
TLE2 FAM BHQ1 GCTCAGATTATCCCCTTCCTGACC
CAGGAGCAT 
 
For preparing the working solutions, primers and probes (stock solution 100 
pmol/µl) were 1:10 diluted in nuclease-free water to target concentration of 10 
pmol/µl. All primers and probes were ordered by Eurofins Genomics (Germany). 
2.2 Methods 
2.2.1 Cell culture 
The cryogenic vials of necessary cell lines were taken from the -80°C freezer 
and quickly thawed in a water bath at 37°C. The cell suspension was then 
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transferred into a 15 ml tube with pre-warmed medium and centrifuged at 300 
g for 5 min. The supernatant was discarded, the cell pellet was resuspended in 
an appropriate medium and placed in a 25 cm2 tissue culture flask with pre-
heated medium. The cells were then cultured in an incubator at 37°C in an 
atmosphere of 5% CO2 and could grow adherently at the bottom of the flask. 
Medium was changed every 2 days. For generating a large number of cells, 
cells were passaged at 70-80% of confluence. Once the cells had dissolved 
with trypsin from the bottom of the flask, than pre-warmed cell culture medium 
was added to inactivate the trypsin. After that, the cells were passaged with a 
ratio of 1: 3 or 1: 4 and transferred into prepared cell culture flasks with fresh 
medium and incubated. 
For determination of cell number, cells were seeded at a defined density, and 
the number of cells using the Neubauer chamber could be determined. For this 
purpose, the cells were trypsinized from the flask bottom and then centrifuged 
in in a 15 ml tube with 5 ml medium at 300 g for 5 min. The supernatant was 
discarded, the cell pellet was resuspended in 5 ml of fresh medium. 10 μl of this 
cell suspension were mixed with 90 μl of NaCl and 100 μl of trypan blue. 10 μl 
of this mixture were then placed in a Neubauer counting chamber and counted 
four squares under the microscope. The number of total counted cells was 
multiplied by 50,000 to obtain the number of cells / ml. 
 
2.2.2 Transient transfection 
In eukaryotic organisms, the RNA interference (RNAi) is a universal mechanism 
which is used to prevent viral attacks and gene regulation [86]. In the laboratory, 
RNA interference (RNAi) is an experimental tool to down-regulate the specific 
genes and to study the function of particular genes or proteins. In this study, 
genes using synthetic siRNAs (small interfering or short interfering RNA) were 
turned off by the siRNA single strand binds to the specific mRNA and induces 
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their selective degradation. 
The siRNA transfection was performed with pre-designed siRNA and 
DharmaFECT transfection reagent (GE Healthcare, Chicago, IL, USA). For 
transient transfection of siRNA, cells were treated with indicated culture 
medium without FBS. First, the cells with the required density and appropriate 
volume were seeded in complete medium depending on the duplicates or 
triplicates were made in experiment. The test siRNA and scrambled siRNA were 
diluted with RNase-free solution to the concentration of 5 μM. Subsequently, 
the siRNAs and the transfection reagent were diluted to the target concentration 
with FBS-free medium and incubated for 10 min at room temperature (RT) 
separately. The mixture with diluted transfection reagent and the per-diluted 
siRNA was incubated 30 min at RT. Finally, full-medium was added to the siRNA 
transfection mix. The prepared transfection mixture was pipetted to the 
previously seeded cells and incubated at 37°C and 5% CO2 for 24 h, than 
changing to the medium and further cultured 24-72 h according to the 
experiment setting or collected directly. An overview of the cell densities and 
volumes of siRNA, transfection, FBS-free and complete medium for 
transfection with 10 nM siRNA used can be found in Table 8. 
 
Table 8. Volume of per well for siRNA-transfection with target 
concentration of 10 nM. 
Wells/Platte 
Cell 
density 
(cells/well) 
siRNA solution 
(μl/well) 
DharmaFECT solution 
(μl/well) 
Cell 
solution 
(μl/well) 
5μM 
siRNA 
(μl) 
FBS-
free 
medium 
(μl) 
DharmaFECT 
(μl) 
FBS-
free 
medium 
(μl) 
96 1 x 104 0.4 9.6 0.2 9.8 180 
24 5 x 104 1 49 0.5 49.5 400 
12 1 x 105 2 98 1 99 800 
6 2 x 105 4 196 2 198 1600 
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2.2.3 RNA extraction 
For cell samples, total RNA was isolated using the RNeasy Mini kits (Qiagen, 
Hilden, Germany) according to the manufacturer's instructions, based on the 
buffer with a high salt content and binding of RNA to silica membrane. After 
washing off steps, contaminants are removed and then eluted RNA in RNase-
free water. 
First, the cell culture medium was removed individually, and the cells were 
washed with 5 ml cold PBS and detached with trypsin enzymatically from the 
bottom of the flask. Cells that could grow in plates were lysed directly after the 
washing step. The lysis buffer RLT was previously added β-mercaptoethanol in 
the ratio 1: 100. For the cell counting of less than 1x106 cells / ml, the cells were 
lysed with a volume of 350 μl buffer, for higher number of cells with a volume of 
600 μl. Subsequently the lysate was homogenized by repeatedly pulling 
through an injection needle.  
Next, equal volume of 70% ethanol as the lysis buffer (350 μl or 600 μl) was 
added into the lysate and mixed. 700 μl of this sample were added in an 
RNeasy column which were in a 2 ml tube, and centrifuged at 10,000 g for 2 
min. The flow-through was discarded and the centrifugation step was repeated 
with the rest of the sample. Then 600 μl wash buffer RW1 and 500 μl of the 
second wash buffer (RPE) were added to the column consecutively. Between 
each two steps 1 min centrifugation at 10,000 g was performed and the flow-
through was discarded. The RNeasy column was then transferred into a new 2 
ml tube and further centrifuged 2 min. Then the column was placed in a 
nuclease-free 1.5 ml tube and 30 μl of RNase-free water was pipetted directly 
onto the silica membrane followed by 2 min incubation to elute the RNA. After 
a final centrifugation (3 min, 10,000 g), the eluate was added in an RNase-free 
1.5 ml tube and immediately placed on ice. Finally, the RNA concentration was 
measured photometrically using the NanoDrop spectrophotometer and the 
RNA stored at -80°C until further usage. 
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For FFPE tissues, total RNA were extracted and enriched using the magnetic-
bead-based XTRAKT FFPE Kit (Stratifyer, Cologne, Germany), according to 
the instructions of manufacturer [87]. First, the 10μm FFPE sections were lysed, 
and the paraffin was melted in 150 μl lyse buffer for 30 min at 80°C with shaking. 
After cooling, 50 μl Proteinase K was added and incubated for 30 min at 65°C 
with shaking. 40 µl MagiX-beads were mixed and added to samples for 
incubating 15 min at RT with shaking. Then the samples were transferred to the 
special tube rack with magnet. The samples were magnetized by 5 min and 
washed three times with wash buffer. After discarding the supernatant, 50 μl 
elution buffer was added and incubated 2 min at RT. The eluate was transferred 
into a fresh tube after incubation and magnetization, determining concentration 
with Nanodrop spectrophotometer. The purified RNA could be analyzed by 
polymerase chain reactions (PCR) directly or stored at -80°C until use. 
 
2.2.4 cDNA synthesis 
The reverse transcription converts RNA into complementary DNA (cDNA), 
which could be used in PCR. For cell samples, it was performed using the M-
MLV Reverse Transcriptase kit from Invitrogen (California, USA). 
The first step was to dilute RNA samples with nuclease-free water to target 
concentration of 2 μg, so that a total volume of 10 μl was achieved. For RNA 
denaturation the diluted RNA samples were incubated for 10 min at 65°C, then 
placed for 3 min on ice. Next the samples were pipetted with cDNA synthesis 
Master Mix (Table 9). 
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Table 9. cDNA synthesis Master Mix for M-MLV reverse 
transcriptase. 
Reagents Volume (μl) 
5x First Strand (M-MLV)-buffer 4 
DTT (100 mM) 2 
dNTP Mix (10 mM) 1 
pdN6 Random Primer (5 mg/ml) 1 
RNase OUT (40 U/μl) 1 
M-MLV Reverse Transcriptase (200 U/μl) 1 
Total Volume 10 
 
The sample was immediately placed in the thermocycler, then incubated 120 
min at 37 °C and heated 15 min at 70 °C to inactivate the enzyme. After 
accomplishment of the cDNA synthesis, the sample was centrifuged briefly and 
stored at -20 °C. 
The reverse transcription for FFPE samples was performed using the 
Superscript III ® reverse transcriptase kit from Invitrogen. This system is 
engineered for higher thermostability, with a longer half-life at 50 °C, and 
reduced RNase H activity, resulting in higher yields of full-length cDNA for more 
complete gene product representation. 
The total volume of each reaction system is 20 μl, including 7 μl primer mix and 
8 μl cDNA synthesis Master Mix, as well as 5 μl RNA sample. The primer mix 
included each 0.5 μl reverse primer, plus 3.5μl nuclease-free water and 1 μl 
dNTPs. For the negative control, nuclease-free water was used instead of RNA 
sample. First, 5 μl RNA sample was added in the primer mix, followed by 
incubating for 10 min at 65 °C, then placed for 3 min on ice. After mixing gently 
with cDNA synthesis Master Mix (Table 10), the sample was immediately placed 
in the thermocycler, heated 120 min at 55 °C and then 15 min at 70 °C to 
inactivate the enzyme. After accomplishment of the cDNA synthesis, the 
sample was centrifuged briefly and stored at -20 °C. 
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Table 10. cDNA synthesis reaction system for Superscript III 
reverse transcriptase. 
  Reagents Volume (μl) 
Primer mix 
Reverse Primers (10 pmol/µl) 2.5 
dNTPs 1 
nuclease-free water 3.5 
 RNA 5 
Master Mix 
5x First Strand (Superscript III)-buffer 4 
0.1 M DDT 1 
RNaseOUT 1 
Superscript III RT (200U/µl) 2 
 
2.2.5 Quantitative PCR 
The PCR method is used for amplification of DNA including DNA polymerase, 
two sequence-specific oligonucleotides (primers), buffer and nucleotides. First, 
the double stranded DNAs are separated into single strands, then the primers 
are bond to the complementary single-stranded DNA (cDNA). In the last step, 
new DNA strands are synthesized by the DNA polymerase with dNTPs. Since 
these three steps are repeated for several cycles, the desired DNA sequence 
is amplified and can be detected. 
For cell samples, SYBR Green-based quantitative PCR (qPCR) was performed 
to determine the gene expression. SYBR Green is a fluorescent dye, which thus 
leads to the increase of the fluorescence intensity during amplification of cDNA 
associated with the PCR product. The more product is formed, the more dye is 
attached. Therefore the fluorescence is proportional to the amount of PCR 
product formed. The Fast SYBR Green Master Mix from Life Technologies 
contains the SYBR Green dye, DNA polymerase and dNTPs with nuclease-free 
water, and cDNA with primer pair for qPCR are prepared in advance (Table 11). 
After a centrifugation at 1850 g for 5 min, the prepared 96-well plate was placed 
in StepOne Plus. The PCR process was initiated at 95 °C for 20 s, then followed 
by 40 cycles of the following temperatures for the amplification of cDNA: 95 °C 
for 3 s, 60 °C for 30 s and 95 °C for 15 s, and the melting curve was available 
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after the process (95 °C for 15 s, 60 °C for 1 min and 95 °C for 15 s). 
 
 
Table 11. SYBR Green qPCR Master Mix. 
Reagents Volume (μl) 
Fast SYBR® Green Master Mix 5 
Nuclease-free water 1.25 
Forward primer (10 pmol/µl) 0.375 
Reverse primer (10 pmol/µl) 0.375 
cDNA 3 
Total Volume 10 
 
 
For FFPE samples, TaqMan probes-based qPCR was performed to determine 
the gene expression. The TaqMan reaction system is a Master Mix, which 
contains DNA polymerase and dNTPs, together with nuclease-free water, 
cDNA, two primers and a probe (Table 13). The probe is labeled with a 
fluorescent reporter dye at the 5 'end and at the 3' end with a quencher. The 
primers and probe can hybridize with the cDNA target sequences. During the 
elongation, the probes which hybridized to the target are cleaved by the DNA 
polymerase between reporter and quencher, exposing reporter dye and 
resulting in increased fluorescence. 
The prepared master mix was centrifuged for 5 min at 1850 g and provided for 
amplification of the samples in the StepOne Plus. The PCR process was started 
initially by denaturation at 95 °C for 20 s, and then followed by 40 cycles of 
amplification (95 °C for 3 s and 60 °C for 30 s). β-Glucuronidase (GUS) and 
calmodulin2 (Calm2) were measured as reference genes [88, 89]. As previously 
described, the relative mRNA expression level was normalized to reference 
genes or control cell line, and determined using the 40-∆CT or 2−ΔΔCT for cell 
culture samples and FFPE samples, depending on the specific analysis [90]. 
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Table 12. TaqMan qPCR Master Mix. 
Reagents Volume(μl) 
TaqMan® Fast Advanced PCR Master Mix 5 
Nuclease-free water 1 
Forward primer (10 pmol/µl) 0.375 
Reverse primer (10 pmol/µl) 0.375 
Probe (10 pmol/μl) 0.25 
cDNA 3 
Total Volume 10 
 
2.2.6 Cell viability assay 
To determine the cell viability, the CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (Promega, Wis, USA) was performed. Increased amounts 
of cells are presented by the increased purple color of the formazan product 
which is soluble in cell culture medium. The amount of formazan can be 
measured photometrically and is proportional to the number of living cells in 
culture. Cells were seeded with 100 μl complete medium in a 96-well plate on 
the first day of the experiment, with the desired density and incubated overnight 
at 37 °C and 5% CO2. The samples were also pipetted in triplicate with the 
empty cell culture medium as control group. On the second day, the 
experimental group and control group at appropriate concentrations with a final 
volume of 100 μl serum-free medium were added to the cells and the cells were 
cultured at 37 °C in CO2 incubator. 20 μl MTS solution was added after 24 h, 
48 h and 72 h respectively and the plate was incubated for 3 h in an incubator. 
Subsequently, the absorbance was measured by microplate reader at 492 nm. 
Each experiment was performed in triplicates. 
 
2.2.7 Colony formation assay 
For colony formation assays, benigne and malignant urothelial cells were 
seeded in six-well plates at a concentration of 5000 cells per well in triplicates, 
and cultured for 7 days before staining viable colonies with crystal violet 
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(Sigma-Aldrich, Darmstadt, Germany). The crystal violet was removed followed 
by 20 min incubation and colonies were air-dry. Colonies were counted under 
the microscope at low magnification. The staining intensity of the colonies was 
quantitated using ImageJ software [91]. 
 
2.2.8 Migration assay 
Cell migration was evaluated by a wound-healing assay. First, the 2-well culture 
inserts (ibidi GmbH, Munich, Germany) were placed in empty 6-well or 12-well 
plate using a sterile tweezer. Next, 70 - 100μl of the appropriate number of cells 
were seeded into each well. After 24 h incubation, culture inserts were carefully 
removed and initial pictures of open wound were taken. Every 6 h, snapshot 
pictures were taken under the inverted microscope until the wound closure. To 
analyze the results of snapshot pictures, the proportion of the wound area was 
quantitated using TScratch software [92]. 
 
2.2.9 GO enrichment and pathways analysis 
2.2.9.1 GO analysis 
Gene Ontology (GO) can be divided into three categories, which covering three 
aspects of biology, including biological process, molecular function, and cellular 
component. The results of the GO enrichment analysis may suggest the 
pathological changes of gene function during the occurrence and development 
of BLCA. 
This method calculates the hypergeometric distribution relationship in the GO 
classification by screening differentially expressed genes related to BLCA. The 
calculation result is expressed by false discovery rate (FDR). The smaller the 
FDR value, the more enriched the differential genes are in the GO classification. 
Therefore, by the GO analysis, it can be predicted which gene may be related 
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to the cellular functional changes [93]. 
 
2.2.9.2 Pathway analysis 
Pathway analysis refers to the methods of identifying related genes or proteins 
within a pathway or building pathway de novo. It mainly analyzes the functional 
pathways or metabolic pathways that may be involved in the target gene, which 
is particularly important in the study of mechanisms. The database in KEGG 
Pathway integrates the current knowledge related to the molecular interaction 
network, such as channels and associations [94]. According to the functions 
and signaling pathways that molecules participate in, the molecular 
composition of each signaling pathway is displayed in the form of Pathway Map. 
By calculating the hypergeometric distribution relationship between the target 
gene and pathway, the corresponding p value is obtained. The smaller the p 
value, the more enriched the differentially expressed genes appear in the 
pathway. 
 
2.2.10 Statistical analysis 
Statistical analyses were performed with SPSS 20.0 (IBM, Chicago, IL, USA) 
and GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA). A 
Kolmogorov–Smirnov (K-S) test was used to determine whether the data were 
normally distributed. Student’s t-tests were used to compare between groups 
of normally distributed numerical data, while Mann-Whitney U and Kruskal-
Wallis tests were used to compare the non-normally distributed numerical data. 
Linear regression was used to determine the efficiency of amplification. 
Spearman tests were used to test the correlation between different gene 
expressions. The cut-off values (2−ΔΔCT value) of the groups with high and low 
ANLN, TLE2 and MIR31HG expression were determined by receiver operating 
MATERIALS AND METHODS 
33 
 
characteristic (ROC) curve analysis in the Mannheim cohort [95]. Similarly, in 
the TCGA cohort, the cut-off value (log2 value) of the groups with high and low 
ANLN, TLE2 and MIR31HG expression was determined by ROC curve analysis. 
The Cox regression model was used for univariable and multivariable analysis 
to calculate hazard ratio (HR). The diagnosis age, gender, smoking status, 
stage, lymph node statues and gene expression were counted in multivariable 
analysis. Survival rates of patients were calculated by the Kaplan-Meier method, 
and comparison was made by the log-rank test. In all cases, p < 0.05 was 
considered statistically significant. 
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3 RESULTS 
3.1 Clinical significance of ANLN, TLE2 and MIR31HG 
3.1.1 Patient population and survival analysis 
The expression of interested genes and clinical significance of patients with 
MIBC was analyze in the Mannheim cohort. Demographic and clinical-
pathological data of 107 patients with MIBC included in the Mannheim cohort 
are shown in Table 1. Median follow-up of the entire cohort was 21 months 
(range 3–121 months) and the median follow-up of surviving patients was 50 
months (range 9–121 months). In total, 53 patients (49.53%) suffered a relapse 
(local relapse n = 6, lymph nodes and/or distant metastases n = 36, unclear 
metastasis pattern n = 11). Of the 56 (52.34%) patients who died during the 
follow-up, 38 (35.51%) of them died because of BLCA. 
 
3.1.2 ANLN and TLE2 expression in MIBC tissues 
To explore the association of ANLN and TLE2 of patients with MIBC, the 
expression of the two genes was detected. The gene expression of ANLN and 
TLE2 was examined in 60 samples of the Mannheim cohort, including 47 males 
and 13 females. The median expression of ANLN was 34.16 (range from 27.48 
to 37.58), with 34.26 (range from 28.15 to 37.58) in male and 33.82 (range from 
27.48 to 37.11) in female. The median expression of TLE2 was 28.82 (range 
from 22.17 to 36.74), with 29.27 (range from 22.30 to 36.74) in male and 27.20 
(range from 22.17 to 33.25) in female. 
For validation, a published dataset was reanalyzed. Bar plots compared the 
gene expression profiles across all 31 tumor samples and paired normal tissues 
from TCGA database. ANLN expression was confirmed to be up-regulated in 
the majority of tumor samples (26/31, 83.87%), while TLE2 was down-regulated 
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in the majority of tumor samples (25/31, 80.64%). In BLCA tumor samples, 
ANLN expression was up-regulated (median expression 16.72) compared to 
normal tissues (median expression 1.54; Figure 3A), while TLE2 expression 
was down-regulated (median expression 22.27) compared to normal tissues 
(median expression 60.99; Figure 3B). The dot-box plots with data normalized 
for log-scale showed that ANLN expression was significantly higher in BLCA 
tumor samples than normal tissues (median expression 4.15 vs. 1.34, and p < 
0.001, Figure 3C). In contrast, TLE2 expression was significantly lower in BLCA 
samples than in normal tissues (median expression 4.54 vs. 5.95, and p < 0.001, 
Figure 3D). 
 
Figure 3. Expression of ANLN and TLE2 in BLCA tumor samples compared with normal 
tissues. (A) ANLN expression was up-regulated in tumors compared with normal tissues based 
on TCGA dataset. (B) TLE2 expression was down-regulated in tumors compared with normal 
tissues based on TCGA data. (C) ANLN expression was significantly higher in BLCA tumor 
samples than normal tissues based on TCGA and GTEx projects. (D) TLE2 expression was 
significantly lower in in BLCA tumor samples than normal tissues based on TCGA and GTEx 
projects. 
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3.1.3 MIR31HG expression was subtype-specific in MIBC tissues 
Through the previous part of the experiment, ANLN and TLE2 have opposite 
expression pattern in BLCA. As a further research object, the expression of 
lncRNA MIR31HG was detected in this section. The expression of MIR31HG 
was examined in 107 samples of the Mannheim cohort, including 79 males and 
28 females. The median expression of MIR31HG was 26.96 (range from 22.35 
to 38.78), with 26.81 (range from 22.35 to 36.95) in male and 27.36 (range from 
24.19 to 38.78) in female. Furthermore, in silico analyses were performed for 
validation. In the TCGA dataset, the expression of MIR31HG was down-
regulated in MIBC (median expression 0.2435 with range of 0.0351 to 0.6769, 
n = 407) compared to normal tissues (median expression 0.3549 with range of 
0.2243 to 0.4703, n = 23, p = 0.0002, Figure 4).  
 
 
Figure 4. Expression of MIR31HG in BLCA tumor and normal tissue samples. In the TCGA 
cohort data, MIR31HG was up-regulated in normal tissues compared with tumors. 
 
To better understand the significance of MIR31HG, expression of MIR31HG 
was analyzed in molecular subtypes of BLCA. Patients with BLCA in the TCGA 
cohort were classified into basal/squamous, luminal, luminal-infiltrated, luminal-
papillary and neuronal subtypes according to mRNA clustering. Among all 
subtypes, expression of MIR31HG in basal/squamous (median expression 7.10 
with range of 0 to 9.96) subtype was the most abundant, which was higher than 
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in luminal (median expression 3.16 with range of 0.13 to 6.8, p < 0.0001), 
luminal-infiltrated (median expression 4.99 with range of 0 to 9.16, p < 0.0001), 
luminal-papillary (median expression 5.53 with range of 0 to 9.92, p = 0.0002), 
and neuronal (median expression 4.92 with range of 0 to 8.7, p = 0.0215) 
subtypes (Figure 5A). By clustering according to a trichotomous molecular 
classifications based on an alternative mRNA clustering of the TCGA cohort, it 
is also determined that the expression of MIR31HG was higher in the basal 
subtype (median expression 7.10 with range of 0 to 9.96) compared to the 
luminal (median expression 5.21 with range of 0 to 10.16) and infiltrated 
(median expression 4.99 with range of 0 to 9.16) subtypes (Figure 5B). 
 
Figure 5. Expression of MIR31HG in molecular subtypes of BLCA. (A)In the TCGA cohort, 
expression of MIR31HG was higher in basal/squamous subtype compared to luminal-infiltrated, 
luminal-papillary, and neuronal subtypes. (B) Expression of MIR31HG was higher in basal 
subtype than in luminal and infiltrated subtypes in patients of the TCGA cohort. 
 
3.1.4 Identification and expression of two splicing variants of MIR31HG 
Four transcript variants of MIR31HG were retrieved from the NCBI nucleotide 
database. Transcript variant 1 (RefSeq ID: NR_027054.2) is the full transcript 
of MIR31HG, containing four exons and three junctions. For simplification, 
transcript variant 2 (RefSeq ID: NR_152877.1) lacking exon 1 was named 
MIR31HGΔE1, and transcript variant 4 (RefSeq ID: NR_152879.1) lacking exon 
3 was named MIR31HGΔE3. A model of the gene sequence of the MIR31HG 
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transcript (ENST00000304425.3) and its two splice variants, MIR31HGΔE1 
and MIR31HGΔE3, is shown in Figure 6A.  
 
 
Figure 6. Expression of MIR31HG and two splice variants in the BLCA cohort. (A) Gene 
model of MIR31HG transcript and splice variants MIR31HGΔE1 and MIR31HGΔE3. (B) In the 
Mannheim cohort, expression of MIR31HG was significantly higher than in the splice variants, 
MIR31HGΔE1 and MIR31HGΔE3. (C) In the TCGA cohort, expression of MIR31HGΔE3 was 
significantly higher in basal compared to luminal subtype. (D) In the Mannheim cohort, 
expression of MIR31HGΔE1 was higher in the high KRT20 group compared to the high KRT5 
group. (E) MIR31HGΔE3 expression was higher in the high KRT5 group compared to the high 
KRT20 group in the Mannheim cohort. 
 
In the Mannheim cohort, a significantly higher expression of MIR31HG (median 
expression 34.7 with range of 22.4 to 38.8) was found compared to the 
transcripts, MIR31HGΔE1 (median expression 35.5 with range of 21.0 to 37.6, 
p = 0.0187) and MIR31HGΔE3 (median expression 36.7 with range of 21.3 to 
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39.6, p = 0.0001, Figure 6B). Expression of MIR31HG junction 3, which reflects 
MIR31HGΔE3 expression, was significant higher in the basal (median 
expression 0.6267281 with range of 0 to 1.538462) compared to the luminal 
(median expression 0.3478261 with range of 0 to 1.052632) subtype in the 
TCGA cohort (p = 0.0081, Figure 6C). KRT5 and KRT20 expression can be 
used as a marker for basal and luminal phenotypes, respectively. The 
expression of MIR31HG was analyzed in terms of KRT5 and KRT20 dependent 
expression. High KRT5 (40-∆CT value >36.55) and high KRT20 (40-∆CT 
value >34.12) were defined as expression above median. MIR31HGΔE1 
expression was higher in the high KRT20 group (p = 0.0395, Figure 6D), and 
MIR31HGΔE3 expression was higher in the high KRT5 group (p = 0.1514, 
Figure 6E). 
3.1.5 ANLN, TLE2 and MIR31HG expressions were associated with copy-
number alterations 
Analysis of ANLN and TLE2 gene expression in association with copy-number 
alterations revealed a genetic alteration rate of 10% (41/407) for ANLN and 5% 
(21/407) for TLE2. Putative copy-number alterations including deep/shallow 
deletion, diploid, gain, and amplification were acquired from GISTIC. The 
majority of copy-number alteration signatures for ANLN were gains and 
amplifications rather than deletions (number 173 vs. 25, 42.51% vs. 6.14%, 
median expression 10.54 vs. 9.45, and p = 0.0002, Figure 7A). For TLE2, most 
samples showed deletion variations rather than amplifications (number 143 vs. 
54, 35.14% vs. 13.27%, median expression 9.63 vs. 9.77, and p = 0.0394, 
Figure 7B). Significantly higher expression of ANLN was observed in the 
subgroup with gain compared to diploid (median expression 10.54 vs. 9.88, and 
p < 0.0001) and deletion (median expression 10.54 vs. 9.45, and p < 0.0001, 
Figure 7C). There were no significant differences in TLE2 expression in the 
subgroups with deletion compared to diploid (median expression 9.63 vs. 9.98, 
RESULTS 
40 
 
and p = 0.1458) or gain (median expression 9.63 vs. 9.73, and p = 0.9190, 
Figure 7D). When gene expression levels were grouped into low and high 
expression, analysis revealed higher rates of amplification/gains in the 
subgroup with higher ANLN expression (n = 86, 56.90%) compared to lower 
ANLN expression (n = 77, 31.95%, Figure 7E). In contrast, amplification was 
only observed in 12.2% (n = 30) of the TLE2 low expression group and in 14.3% 
(n = 22) of the TLE2 high expression group (Figure 7F). Furthermore, higher 
rates of deletion were seen in the TLE2 low expression subgroup than in the 
TLE2 high expression subgroup (n = 102, 41.46% vs. n = 40, 25.97%). 
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Figure 7. ANLN and TLE2 expression in association with copy-number alterations. (A) 
ANLN showed 6.14% of shallow/deep deletion, 51.35% of diploid, and 42.51% of 
gain/amplification. (B) TLE2 showed 35.14% of shallow/deep deletion, 51.60% of diploid and 
13.27% of gain/amplification. (C) Significant higher expression of ANLN was observed in the 
subgroup with gain than diploid (median expression 10.54 vs. 9.88, and p < 0.0001) and 
deletion (median expression 10.54 vs. 9.45, and p < 0.0001). (D) No significant differences of 
TLE2 expression were found in the subgroups with deletion against diploid (median expression 
9.63 vs. 9.98, and p = 0.1458) or gain (median expression 9.63 vs. 9.73, and p = 0.9190). The 
gene expression levels of ANLN and TLE2 were grouped into high and low expression. (E) In 
the subgroup with lower ANLN expression, diploid (n = 143, 59.34%) was more frequently 
observed than gain (n = 77, 31.95%) and deletion (n = 21, 8.71%). The subgroup with higher 
ANLN expression is associated with a higher percentage of gain (n = 86, 56.90%) than diploid 
(n = 62, 41.10%) and deletion (n = 3, 2.00%). (F) TLE2 was mainly expressed in the subgroup 
with deletion and diploid in TLE2 low expression (n = 102, 41.46% in deletion; n = 114, 46.34% 
in diploid) and TLE2 high expression (n = 40, 25.97% in deletion; n = 92, 59.74% in diploid). 
Gain was observed in only 12.2% (n = 30) in TLE2 low expression group and in 14.29% (n = 
22) in the TLE2 high expression group. 
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Similar to the analysis for ANLN and TLE2, the association between MIR31HG 
expression and copy-number alterations were analyzed in the TCGA dataset. 
The analysis of MIR31HG copy-number alterations revealed a genetic 
alteration rate of 23% (92/407). Putative copy-number alterations including 
deep/shallow deletion, diploid, gain, and amplification were also acquired from 
the GISTIC algorithm. MIR31HG showed 52.97% of shallow / deep deletion (n 
= 214), 31.44% of diploid (n = 127), and 15.59% of gain/amplification (n = 63, 
Figure 8A). The expression of MIR31HG was significantly higher in the 
subgroup with gain (median expression 7.46, p < 0.0001) and diploid (median 
expression 7.12, p < 0.0001) compared to those with a deletion alteration 
(median expression 4.77, Figure 8B). High expression of MIR31HG was found 
in the subgroup with deletion and diploid alteration than in gain (n = 47, 20.44% 
in gain; n = 99, 43.04% in diploid; n = 84, 36.52% in deletion), while low 
expression was observed in the subgroup with deletion alteration, compared to 
diploid and gain (n = 15, 8.67% with gain; n = 28, 16.18% with diploid; n = 130, 
75.15% with deletion, Figure 8C). 
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Figure 8. MIR31HG expression in association with copy-number alterations. (A) 
MIR31HG showed 52.97% of shallow / deep deletion, 31.44% of diploid and 15.59% of 
gain/amplification. (B) Significantly higher expression of MIR31HG was observed in the 
subgroup with gain (median expression 7.46) and diploid (median expression 7.12) compared 
to deletion (median expression 4.77). (C) High expression of MIR31HG was observed in the 
subgroup with deletion and diploid than in gain (n = 47, 20.44% in gain; n = 99, 43.04% in 
diploid; n = 84, 36.52% in deletion), while low expression was observed in the subgroup with 
deletion compared to diploid and gain (n = 15, 8.67% in gain; n = 28, 16.18% in diploid; n= 130, 
75.15% in deletion). 
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3.1.6 ANLN and TLE2 as risk markers for prognostic prediction after RC 
After identifying the expression and copy-number alterations of ANLN and TLE2, 
the association with clinical outcome and parameters was analyzed in the 
Mannheim and the TCGA cohort. In the Mannheim cohort, patients with high 
ANLN expression showed worse OS (n = 22 with low expression, n = 38 with 
high expression; median survival, 21 vs. 10 months, and p = 0.0010) and DSS 
(n = 20 with low expression, n = 40 with high expression; median survival, 21 
vs. 10 months, and p = 0.0060) after RC than patients with low expression 
(Figure 9A, B). Conversely, patients with high TLE2 expression displayed more 
favorable OS (n = 29 with high expression, n = 31 with low expression; median 
survival, 15 vs. 9 months, and p = 0.0236) and DSS (n = 29 with high expression, 
n = 31 with low expression; median survival, 31 vs. 13 months, and p = 0.2083) 
than patients with low expression (Figure 9C, D). The gene expression levels 
were not normally distributed. 
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Figure 9. Kaplan–Meier plots of overall survival (OS) and disease-free survival (DSS) 
survival associated with ANLN and TLE2 risk stratification in the Mannheim cohort. (A, 
B) The group with high ANLN expression showed worse OS and DSS than the group with low 
expression. (C, D) The group with high TLE2 expression displayed more favorable OS and 
DSS than the group with low expression. 
 
To further understand the outcome significance of ANLN and TLE2 in BLCA, 
multiple regression analysis were performed. In the univariable and 
multivariable Cox regression analysis, ANLN (p = 0.0020 and p = 0.0390, 
respectively) and TLE2 (p = 0.0120 and p = 0.0020, respectively) expression 
were independent predictors. Furthermore, lymph node status was identified as 
an independent prognostic factor by both analyses (p = 0.0030 and p = 0.0240), 
LVI (p = 0.0040) was only by the univariable Cox regression analysis 
independent (Table 13). No significant correlation was observed between 
patient age, patient gender, or stage of tumor and ANLN and TLE2 expression. 
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Table 13. Uni- and multivariable Cox regression analysis of ANLN and 
TLE2 with clinicopathological features in the Mannheim cohort. 
Factor 
Univariable Multivariable 
HR (95% CI) 
p 
Value 
HR (95% CI) 
p 
Value 
Diagnosis 
Age 
    
<70 vs. ≥70 0.584 (0.269–
1.269) 
0.174 0.874 (0.359–
2.127) 
0.767 
Gender 
    
Male vs. 
Female 
1.128 (0.405–
3.140) 
0.957 1.820 (0.587–
5.643) 
0.300 
Stage 
    
T1/T2 vs. T3/4 0.168 (0.015–
1.832) 
0.128 0.360 (0.127–
1.023) 
0.055 
LVI 
    
Negative vs. 
Positive 
0.542 (0.359–
0.819) 
0.004 0.380 (0.048–
2.998) 
0.358 
Lymph node 
Statues 
    
Negative vs. 
Positive 
0.549 (0.371–
0.813) 
0.003 0.612 (0.399–
0.938) 
0.024 
ANLN 
    
Low vs. High 0.220 (0.084–
0.575) 
0.002 0.328 (0.114–
0.945) 
0.039 
TLE2 
    
Low vs. High 0.305 (0.121–
0.769) 
0.012 0.172 (0.057–
0.519) 
0.002 
Note: HR = hazard ratio, CI = confidence interval, LVI = lymphovascular 
invasion, significant p values are bold. 
 
These results were validated in the TCGA cohort. Higher ANLN expression was 
associated with worse OS (n = 246 with low expression, n = 161 with high 
expression; median survival, 18.07 vs. 15.31 months, and p = 0.0144) and DFS 
(n = 246 with low expression, n = 161 with high expression; median survival, 
18.82 vs. 13.99 months, and p = 0.0045, Figure 10A, B). In contrast, higher 
TLE2 expression was associated with more favorable OS (n = 250 with low 
expression, n = 157 with high expression; median survival, 16.69 vs. 18.99 
months, and p = 0.0054) and DFS (n = 250 with low expression, n = 157 with 
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high expression; median survival, 15.31 vs. 16.79 months, and p = 0.0094, 
Figure 10C, D). Further analysis of the TCGA BLCA cohort according to clinical 
stage showed that lower ANLN (n = 77 with low expression, n = 41 with high 
expression; median survival, 23.43 vs. 19.66 months, and p = 0.0397) and 
TLE2 (n = 67 with low expression, n = 51 with high expression; median survival, 
17.94 vs. 20.37 months, and p = 0.0100) expression in the pT2 subgroup could 
be attributed to a good and poor prognosis of OS, respectively (Figure 10E, F). 
Furthermore, the gene expression of ANLN and TLE2 was analyzed in 
subtypes of MIBC. Notably, in the TCGA cohort, ANLN expression in patients 
with MIBC and basal subtype was associated with worse OS (n = 61 with low 
expression, n = 81 with high expression; median survival, 20.37 vs. 13.96 
months, and p = 0.0467, Figure 10G) compared with the whole TCGA cohort. 
Higher TLE2 expression showed better OS in patients with MIBC and luminal 
subtype (n = 130 with high expression, n = 115 with low expression; median 
survival, 19.48 vs. 17.87 months, and p = 0.0181, Figure 10H) compared with 
the whole TCGA cohort. The gene expression levels were not normally 
distributed. 
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Figure 10. Kaplan–Meier plots of OS and DFS associated with ANLN and TLE2 risk 
stratification in the TCGA cohort. (A, B) Higher ANLN expression showed worse OS and 
DFS. (C, D) Higher TLE2 expression showed more favorable OS and DFS. (E, F) In the T2 
subgroup, low ANLN and TLE2 expression showed good and poor prognosis of OS, 
respectively. (G, H) Higher ANLN expression showed worse OS in basal subtype and higher 
TLE2 showed better OS in luminal subtype. 
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Besides, in the TCGA cohort, correlation between ANLN and TLE2 expression 
and stage showed that ANLN was significantly expressed in pT3 and pT4 
(higher stages, median expression 9.95 vs. 10.16, and p = 0.0109, Figure 11A), 
while TLE2 was dominantly expressed in pT2 (lower stage, median expression 
9.88 vs. 9.73, and p = 0.0228, Figure 11B). 
 
 
Figure 11. Correlation between ANLN and TLE2 expression and stage from the TCGA 
cohort. (A) The TCGA cohort showed that ANLN was significantly expressed in higher pT3-4 
stages (median expression 9.95 vs. 10.16, p = 0.0109). (B) TLE2 was dominantly expressed in 
lower pT2 stage (median expression 9.88 vs. 9.73, p = 0.0228). 
 
In the univariable Cox regression analysis of clinicopathological features, stage 
(p < 0.001), lymph node status (p < 0.001), ANLN (p = 0.0160), and TLE2 (p = 
0.0060) expression were independent. Furthermore, stage (p = 0.0060), ANLN 
(p = 0.0180), and TLE2 (p = 0.0400) were also independent prognostic factors 
in the multivariable Cox regression analysis (Table 14). 
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Table 14. Uni- and multivariable Cox regression analysis of ANLN and 
TLE2 with clinicopathological features in the TCGA cohort. 
Factor 
Univariable Multivariable 
HR (95% CI) p Value HR (95% CI) 
p 
Value 
Diagnosis Age 
    
<70 vs. ≥70 1.260 (0.931–
1.705) 
0.134 1.195 (0.701–
2.038) 
0.513 
Gender 
    
Male vs. 
Female 
1.257 (0.902–
1.751) 
0.177 1.531 (0.724–
3.240) 
0.265 
Smoking 
Status 
    
No vs. Yes 1.335 (0.940–
1.897) 
0.106 1.851 (0.503–
6.811) 
0.355 
Stage 
    
T2 vs. T3/4 1.950 (1.393–
2.731) 
<0.001 1.646 (1.156–
2.342) 
0.006 
Lymph node 
Statues 
    
Negative vs. 
Positive 
2.145 (1.596–
2.883) 
<0.001 1.989 (1.461–
2.707) 
<0.001 
ANLN 
    
Low vs. High 1.439 (1.070–
1.934) 
0.016 1.438 (1.064–
1.943) 
0.018 
TLE2 
    
Low vs. High 0.636 (0.460–
0.880) 
0.006 1.415 (1.015–
1.973) 
0.040 
Note: HR = hazard ratio, CI = confidence interval, significant p values are bold. 
 
3.1.7 MIR31HG as prognostic marker for MIBC patients with basal subtype 
Unlike ANLN and TLE2, no significant association between expression of 
MIR31HG and patient outcome was found in the whole TCGA cohort. Notably, 
survival analysis showed that patients of the TCGA cohort with basal subtype 
were significantly associated with OS and DFS based on MIR31HG risk 
stratification. The group with high MIR31HG expression showed a worse OS 
compared to the group with low expression (median survival, 28 vs. 16 months, 
p = 0.0081, Fig. 12A). Furthermore, the group with high MIR31HG expression 
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showed a worse DFS compared to the group with low expression (median 
survival, 27 vs. 15 months, p = 0.1383, Fig. 12B). 
 
 
 
Figure 12. Kaplan-Meier plot of OS and DFS associated with MIR31HG risk stratification. 
(A) In the TCGA cohort with basal subtype, the group with high MIR31HG expression showed 
a worse OS compared to the group with low expression (median survival, 28 vs. 16 months, p 
= 0.0081). (B) In the TCGA cohort with basal subtype, the group with high MIR31HG expression 
showed a worse DFS compared to the group with low expression (median survival, 27 vs. 15 
months, p = 0.1383). 
 
3.1.8 Splicing variants of MIR31HG as prognostic marker for patients with 
MIBC 
Kaplan-Meier analysis and the log-rank test were used to evaluate the 
association of the expression of two MIR31HG splice variants with OS and DFS 
in the Mannheim cohort. For the full-length transcript of MIR31HG, no 
significant difference in OS (median survival 18 vs. 21 months, p = 0.2610, 
Figure 13A) and DFS (median survival 11 vs. 9 months for MIR31HG, p = 
0.8978, Figure 13B) was found between high and low expression levels. 
Tumors with both high MIR31HGΔE1 (median survival 15 vs. 38 months, p = 
0.0394, Figure 13C) and MIR31HGΔE3 expression (median survival 12 vs. 30 
months, p = 0.0093, Figure 13E) showed a worse OS. The groups with high 
MIR31HGΔE1 (median survival 7 vs. 25 months, p = 0.0038, Figure 13D) and 
MIR31HGΔE3 (median survival 9 vs. 15 months, p = 0.1252, Figure 13F) 
expression also showed a worse DFS. Tumors with high expression of 
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MIR31HG Exon1-2 (Junction 3), which could partially present as MIR31HGΔE3, 
showed a worse OS than the group with low expression, in the TCGA cohort 
with basal subtype (median survival 15 vs. 17 months, p = 0.0298, Figure 13G). 
No significant difference was found for DFS (median survival 12 vs. 15 months, 
p = 0.5670, Figure 13H). 
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Figure 13. Kaplan-Meier plot of OS and DFS associated with MIR31HG and its splice 
variants risk stratification. (A, B) In the Mannheim cohort, no significant correlation was found 
with OS (median survival 18 vs. 21 months) and DFS (median survival 11 vs. 9 months for 
MIR31HG) in the group with full-length transcript of MIR31HG. (C, D) The group with high 
MIR31HGΔE1 expression showed a worse OS (median survival 15 vs. 38 months) and DFS 
(median survival 7 vs. 25 months) compared to the group with low expression. (E, F) The group 
with high MIR31HGΔE3 expression showed a worse OS (median survival 12 vs. 30 months) 
and DFS (median survival 9 vs. 15 months) compared to the group with low expression. (G) In 
the TCGA cohort, the group with high Junction 3 expression showed worse OS than the group 
with low expression (median survival, 17 vs. 14 months, p = 0.0298). (H) No significant 
difference was observed in DFS between the group with high and low Junction 3 expression 
(median survival, 17 vs. 15 months, p = 0.5670). 
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In the univariable Cox regression analysis regarding the Mannheim cohort, 
MIR31HGΔE1 (p = 0.032) and MIR31HGΔE3 (p = 0.007) expression, as well 
as the stage of cancer, were found to be predictive for patient outcome. In the 
multivariable Cox regression analysis regarding the Mannheim cohort, only 
MIR31HGΔE3 was identified as an independent prognostic factor (p = 0.016). 
No significant correlation was observed between the full-length transcript of 
MIR31HG and OS of the patients in both analyses, nor with patient age, patient 
gender, lymph node status, and LVI (Table 15). 
 
Table 15. Uni- and multivariable cox regression analysis of MIR31HG and 
its splice variants with clinicopathological features in the Mannheim 
cohort. 
 
Factor 
Univariable  Multivariable 
HR (95% CI) p  HR (95%CI) p 
Diagnosis Age      
＜70 vs. ≥70 0.693(0.401-1.198) 0.189  0.524(0.263-1.043) 0.066 
Gender      
Male vs. Female 0.907(0.495-1.662) 0.752  1.077(0.538-2.156) 0.834 
Stage      
T2 vs. T3/4 0.401(0.202-0.797) 0.009  0.581(0.278-1.216) 0.149 
LVI      
Negative vs. 
Positive 
0.608(0.083-4.473) 0.625  0.482(0.061-3.787) 0.487 
Lymphnode 
Statues 
     
Negative vs. 
Positive 
0.724(0.416-1.260) 0.253  0.936(0.486-1.800) 0.842 
MIR31HG      
Low vs. High 1.614(0.688-3.784) 0.271  1.943(0.574-6.577) 0.286 
MIR31HGΔE1      
Low vs. High 2.249(0.999-5.067) 0.032  1.535(0.642-3.671) 0.335 
MIR31HGΔE3      
Low vs. High 2.679(1.312-5.472) 0.007  2.507(1.183-5.311) 0.016 
Note: HR = hazard ratio, CI = confidence interval, LVI = lymphovascular 
invasion, significant p values are bold. 
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3.2 Function of ANLN, TLE2 and MIR31HG in BLCA tumorigenesis 
3.2.1 ANLN and TLE2 are associated with signaling pathways and therapeutic 
targets in BLCA 
Beside the expression and survival analyses, the functional role was also 
analyzed. Thus, the protein-protein interactions of ANLN and TLE2 were 
analyzed by Search Tool for Retrieval of Interacting Genes/Proteins (STRING, 
Figure 14).  
 
Figure 14. Protein-protein interactions of ANLN and TLE2. Protein-protein interactions 
predicted by STRING showed the interaction network of ANLN and TLE2 based on curated 
databases and experimental determination. 
 
ANLN protein was predicted to have interactions with abnormal spindle protein 
homolog (ASPM), mitotic checkpoint serine/threonine-protein kinase (BUB1), 
centrosomal protein 55 (CEP55), kinesin family member 11 (KIF11), Rac 
GTPase activating protein 1 (RACGAP1), cyclin dependent kinase 1 (CDK1), 
and serine/threonine protein kinase (PBK). TLE2 protein was predicted to have 
interactions with transcription factor 7 (TCF7), transcription factor 7-like 1 
(TCF7L1), transcription factor 7-like 2 (TCF7L2), lymphoid enhancer-binding 
factor 1 (LEF1), catenin beta-1 (CTNNB1), cyclin D-type binding protein 1 
(CDBP1), Notch homolog 1 (NOTCH1), histone deacetylase 1 (HDAC1), hairy 
and enhancer of split-1 (HES1), and recombination signal binding protein for 
immunoglobulin kappa J region (RBPJ). The number of counted gene sets and 
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the false discovery rate (FDR) for each Gene Ontology (GO) term are shown in 
Table 16. 
Table 16. GO enrichment analysis by Enrichr indicated the significant 
GO terms for ANLN and TLE2 including biological process, molecular 
function, cellular component, and KEGG pathways. 
Gene Dataset Pathway ID Pathway Description 
Count in 
Gene Set 
False Discovery 
Rate 
ANLN 
Biological Process (GO) 
GO:0007067 mitotic nuclear division 10 1.42E-13 
GO:0051301 cell division 9 1.99E-10 
GO:1903047 mitotic cell cycle process 9 7.57E-09 
GO:0000278 mitotic cell cycle 9 1.69E-08 
GO:0051302 regulation of cell division 7 2.14E-08 
Molecular Function (GO) 
GO:0005524 ATP binding 6 0.0483 
GO:0043168 anion binding 7 0.0483 
Cellular Component (GO) 
GO:0005819 spindle 7 3.16E-08 
GO:0044430 cytoskeletal part 9 4.71E-07 
GO:0015630 microtubule cytoskeleton 8 1.33E-06 
GO:0030496 midbody 5 1.33E-06 
GO:0072686 mitotic spindle 4 1.64E-06 
TLE2 
Biological Process (GO) 
GO:0000122 negative regulation of transcription from RNA polymerase II promoter 9 2.39E-08 
GO:0043588 skin development 7 2.39E-08 
GO:0048864 stem cell development 7 2.93E-08 
GO:2000736 regulation of stem cell differentiation 6 3.28E-08 
GO:0009790 embryo development 9 5.72E-08 
Molecular Function (GO) 
GO:0003700 transcription factor activity, sequence-specific DNA binding 9 7.79E-08 
GO:0044212 transcription regulatory region DNA binding 8 7.79E-08 
GO:0003682 chromatin binding 7 5.90E-07 
GO:0001047 core promoter binding 5 2.16E-06 
GO:0070491 repressing transcription factor binding 4 4.10E-06 
Cellular Component (GO) 
GO:0005667 transcription factor complex 7 3.16E-08 
GO:0005654 nucleoplasm 11 1.54E-07 
GO:0031981 nuclear lumen 10 3.92E-05 
GO:0070369 beta-catenin-TCF7L2 complex 2 8.60E-05 
GO:0002193 MAML1-RBP-Jkappa- ICN1 complex 2 0.000129 
KEGG Pathways 
5216 Thyroid cancer 5 3.57E-10 
4310 Wnt signaling pathway 6 2.38E-09 
4330 Notch signaling pathway 5 2.38E-09 
5213 Endometrial cancer 5 2.38E-09 
5200 Pathways in cancer 7 2.75E-09 
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The interaction network based on curated databases and experimentally 
derived results showed that key molecules in signaling pathways were 
significantly correlated with ANLN and TLE2, including cell proliferation (FDR = 
1.99−10), Notch signaling (FDR = 2.38−9), Wnt signaling (FDR = 2.38−9), and 
hormone receptor (FDR = 3.16−8). The correlation with important therapeutic 
targets in BLCA, including epidermal growth factor receptor (EGFR) (p = 7.73−31 
for ANLN and p = 1.78−14 for TLE2), Erb-B2 receptor tyrosine kinase 2 (ERBB2) 
(p = 3.44−13 for ANLN and p = 1.96−43 for TLE2), fibroblast growth factor receptor 
3 (FGFR3) (p = 6.52−9 for ANLN and p = 0.0016 for TLE2), and programmed 
death-ligand 1 (PD-L1) (p = 2.89−18 for ANLN and p = 1.07−18 for TLE2) were 
found to be significantly correlated with ANLN and TLE2 based on TCGA data 
(Table 17). 
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Table 17. Correlation of ANLN and TLE2 with key molecules in signaling 
pathways and therapeutic targets. 
Correlated Gene 
ANLN TLE2 
Correlation 
Coefficient 
p Value 
Correlation 
Coefficient 
p Value 
Cell proliferation 
CDK1 0.594 3.98 × 10−40 −0.338 2.63 × 10−12 
RACGAP1 0.725 1.41 × 10−67 −0.451 9.46 × 10−22 
MKI67 0.711 7.56 × 10−64 −0.396 1.07 × 10−16 
FOXM1 0.688 2.98 × 10−58 −0.4 4.46 × 10−17 
Notch signaling 
NOTCH1 0.109 0.027294 −0.19 0.000115 
RBPJ −0.196 6.6 × 10−5 0.05 0.311468 
Wnt signaling 
TCF7 0.067 0.175097 0.006 0.89689 
TCF7L1 0.162 0.001066 −0.267 4.75 × 10−8 
TCF7L2 −0.186 0.000164 0.23 2.84 × 10−6 
LEF1 −0.101 0.041347 −0.026 0.596286 
CTNNB1 0.237 1.29 × 10−6 −0.276 1.6 × 10−8 
Hormone receptor 
signaling 
AR −0.185 0.000171 0.388 4.9 × 10−16 
ESR1 −0.003 0.944815 −0.048 0.332592 
ESR2 −0.191 0.00011 0.334 4.33 × 10−12 
FOXA1 −0.38 1.89 × 10−15 0.505 9.11 × 10−28 
GATA3 −0.403 2.33 × 10−17 0.65 2.80 × 10−50 
Therapeutic targets 
EGFR 0.53 7.73 × 10−31 −0.368 1.78 × 10−14 
ERBB2 −0.35 3.44 × 10−13 0.613 1.96 × 10−43 
FGFR3 −0.283 6.52 × 10−9 0.156 0.001575 
PIK3CA 0.426 2.19 × 10−19 −0.264 6.34 × 10−8 
CDK4 0.207 2.68 × 10−5 −0.267 4.69 × 10−8 
HRAS −0.023 0.648147 −0.183 0.000202 
PDCD1 0.0881 0.0754 −0.313 1.07 × 10−10 
PD-L1 0.414 2.89 × 10−18 −0.419 1.07 × 10−18 
CTLA4 0.0963 0.052 −0.363 3.71 × 10−14 
EZH2 0.446 2.51 × 10−21 −0.162 0.001009 
Note: Correlation coefficient values above 0.4 and below −0.4 are bold. 
 
It is noteworthy that ANLN was positively correlated with cell proliferation 
markers including CDK1 (ρ = 0.594, p = 3.98−40), RACGAP1 (ρ = 0.725, p = 
1.41−67), marker of proliferation Ki-67 (MKI67) (ρ = 0.711, p = 7.56−64), and 
forkhead box M1 (FOXM1) (ρ = 0.688, p = 2.98−58). In contrast, TLE2 was 
negatively correlated with cell proliferation molecules involving CDK1 (ρ = -
0.338, p = 2.63−12), RACGAP1 (ρ = -0.451, p = 9.46−22), MKI67 (ρ = -0.396, p = 
1.07−16), and FOXM1 (ρ = -0.400, p = 4.46−17). TLE2 was also correlated with 
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molecules involved in Wnt signaling including CTNNB1 (ρ = -0.276, p = 1.6−8) 
and hormone receptors including forkhead box A1 (FOXA1) (ρ = 0.505, p = 
9.11−28) and GATA binding protein 3 (GATA3) (ρ = 0.65, p = 2.8−50; Table 18). 
Further, expression of RACGAP1, MKI67, FOXM1, CDK1, CTNNB1, and 
GATA3 were examined in the Mannheim cohort. This analysis showed that 
ANLN was significantly correlated with RACGAP1 (ρ = 0.455, p < 0.0001), 
FOXM1 (ρ = 0.549, p < 0.0001), MKI67 (ρ = 0.577, p < 0.0001), and CDK1 (ρ 
= 0.763, p < 0.0001; Figure 15A–D). TLE2 was significantly correlated with 
GATA3 (ρ = 0.409, p = 0.0012) and CTNNB1 (ρ = 0.363, p = 0.0070) (Figure 
15E, F). Similar expression data was also detected in the benigne and 
malignant urothelial cell lines. 
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Figure 15. Correlation of selected genes in the Mannheim cohort. ANLN was significantly 
correlated with RACGAP1 (A), FOXM1 (B), MKI67 (C), and CDK1 (D). TLE2 was significantly 
correlated with GATA3 (E) and CTNNB1 (F). 
 
3.2.2 Molecular subtype specificity of ANLN and TLE2 
To comprehensively elucidate the role of ANLN and TLE2 in BLCA, cell lines 
and tissues of different molecular subtype were analyzed. Published RNA-seq 
data from the Cancer Cell Line Encyclopedia showed ANLN and TLE2 
expression levels in TPM (transcripts per million) for 25 BLCA cell lines, with 
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different molecular subtypes of each (basal, luminal, and mixed; Figure 16B). 
Cell lines that were classified as basal subtypes, including UMUC3 and 
SCaBER, showed slightly higher expression of ANLN, while TLE2 dominantly 
expressed in cell lines classified as luminal subtypes, e.g., RT112 and RT4. 
qPCR based on SYBR Green showed relative expression of ANLN and TLE2 
in five malignant urothelial cell lines (RT4, RT112, UMUC3, T24, and ScaBER), 
which correspond with the RNA-seq data (Figure 16A). Similarly, in patients 
with BLCA (TCGA, Provisional), expression of ANLN was higher in the basal 
than in the luminal subtypes (median expression 10.93; range 6.1–13.01 vs. 
median expression 9.64; range 4.87–12.25, p < 0.0001, Figure 16C) according 
to the mRNA clustering. In contrast, TLE2 showed an opposite trend with a 
higher expression in luminal than basal subtypes (median expression 10.41; 
range 5.04–12.55 vs. median expression 7.41, range 1.79–12.25, p < 0.0001, 
Figure 16D).  
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Figure 16. Expression of ANLN and TLE2 in different subtypes of BLCA. (A) qPCR showed 
relative expression of ANLN and TLE2 in five malignant urothelial cell lines (RT4, RT112, 
UMUC3, T24, and ScaBER). (B) In silico RNA-seq data from the Cancer Cell Line Encyclopedia 
showed expression level in TPM (transcripts per million) for ANLN and TLE2 in 25 BLCA cell 
lines with different molecular subtypes of each. (C) Expression of ANLN was higher in basal 
than luminal subtype (median expression 10.93 with range of 6.1 to 13.01 vs. median 
expression 9.64 with range of 4.87 to 12.25, p < 0.0001) in patients with BLCA. (D) TLE2 
expression was higher in luminal than basal subtype (median expression 10.41 with range of 
5.04 to 12.55 vs. median expression 7.41 with range of 1.79 to 12.25, p < 0.0001). 
 
In addition, the basal subtype marker KRT5 and the luminal subtype marker 
KRT20 were analyzed in the Mannheim cohort. KRT5 was significantly 
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correlated with ANLN (ρ = 0.278, p = 0.042; Figure 17A), and KRT20 was 
significantly correlated with TLE2 (ρ = 0.296, p = 0.026; Figure 17B). The 
expression of ANLN and TLE2 were also analyzed in the group with high KRT5 
and the high KRT20 expression, which were classified based on median 
expression of KRT5 and KRT20. It was observed that ANLN expression was 
higher in the high KRT5 group than in the high KRT20 group (p = 0.1119, Figure 
17C), and TLE2 expression was higher in the high KRT20 group than in the 
high KRT5 group (p = 0.1413, Figure 17D). 
 
 
Figure 17. ANLN and TLE2 expression was associated with basal and luminal subtype 
markers. Correlation of KRT5 and ANLN (A) and KRT20 and TLE2 (B) in the Mannheim cohort. 
(C) ANLN expression was higher in the high KRT5 group than in the high KRT20 group (p = 
0.1119). (D) TLE2 expression was higher in the high KRT20 group than in the high KRT5 group 
(p = 0.1413). 
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3.2.3 Expression of MIR31HG in BLCA cell lines with specificity 
Similar as ANLN and TLE2, the role of MIR31HG was assessed in BLCA cell 
lines with different subtypes. Expression of MIR31HG was detected in a normal 
urothelial cell line (UROtsa) and three BLCA cell lines (SCaBER, UMUC3 and 
T24) by qRT-PCR. Significantly lower expression of MIR31HG was observed in 
UMUC3 (mean expression 33.59, p = 0.0003) and T24 cells (mean expression 
32.34, p < 0.0001) compared with UROtsa cells (mean expression 23.64). In 
contrast, expression of MIR31HG was higher in SCaBER cells (mean 
expression 35.53, p = 0.0200) compared to UROtsa cells. The lowest level of 
MIR31HG expression was observed in RT112 (mean expression 21.03, p < 
0.0001) and RT4 cells (mean expression 34.01, p < 0.0001, Figure 18). 
 
 
Figure 18. Expression of MIR31HG in BLCA cell lines. In a normal urothelial cell line 
(UROtsa) and five BLCA cell lines (SCaBER, UMUC3, T24, RT112 and RT4), expression of 
MIR31HG was detected by qPCR. MIR31HG expression was significantly lower in UMUC3 and 
T24 cells, and higher in SCaBER cells compared to UROtsa cells. The lowest MIR31HG 
expression was observed in RT112 and RT4 cells. 
 
MIR31HG expression was also analyzed in RNA-seq data from the Cancer Cell 
Line Encyclopedia containing 25 BLCA cell lines, including 20 bladder urothelial 
cell carcinomas, a bladder squamous cell carcinoma, and four bladder 
carcinoma cell lines from unknown primaries. The data showed that MIR31HG 
expression levels in SCaBER cells (expression level: 10 TPM) were higher than 
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in RT112 (expression level: 0 TPM), RT4 (expression level: 0 TPM), and 
UMUC3 cells (expression level: 3 TPM, Figure 19). 
 
 
Figure 19. Expression of MIR31HG in BLCA cell lines and tissue samples based on in 
silico data. RNA-seq data from the Cancer Cell Line Encyclopedia showed expression levels 
in TPM (transcripts per million) for MIR31HG in 25 BLCA cell lines. 
 
3.2.4 MIR31HG is required for BLCA cell proliferation and migration 
To evaluate the possible role of MIR31HG in BLCA, a pool of four siRNAs 
against MIR31HG (designated si-MIR31HG, set of 4) were transfected in T24, 
UMUC3, and SCaBER cells. T24, UMUC3, and SCaBER cells with MIR31HG 
knockdown by siRNA showed lower cellular viability at three time points 
compared to the control group transfected with scramble siRNA (si-NC; T24: p 
= 0.0068 for 24 h, p = 0.0186 for 48 h, p = 0.0067 for 72 h, Figure 20A; UMUC3: 
p = 0.0073 for 24 h, p = 0.0096 for 48 h, p = 0.0179 for 72 h, Figure 20B; 
RESULTS 
66 
 
SCaBER: p = 0.0047 for 24 h, p = 0.0137 for 48 h, p = 0.0002 for 72 h, Figure 
20C).  
 
Figure 20. MIR31HG is required for proliferation of BLCA cells. (A-C) Cell viability was 
quantified using the MTS assay. T24 (A), UMUC3 (B) and SCaBER (C) cells with MIR31HG 
knockdown by siRNA showed lower cellular viability compared with control group with scramble 
siRNA (si-NC). 
 
Moreover, colony formation was detected by culturing cells in a 6-well plate and 
stained with crystal violet after 7 days. T24, UMUC3, and SCaBER cells with 
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MIR31HG knockdown showed fewer cell colonies compared to the control 
group (Figure 21A). The staining intensity of the colony formation assay was 
quantified by calculating the colony intensity percentage. BLCA cells with 
MIR31HG knockdown showed a reduced formation of colonies compared to the 
control group (p = 0.0198 for T24, p = 0.03 for UMUC3, p = 0.0058 for SCaBER, 
Figure 21B).  
 
Figure 21. MIR31HG is required for colony formation of BLCA cells. (A) Colony formation 
was detected by measuring the stained cells after 7 days. T24, UMUC3, and SCaBER cells 
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with MIR31HG knockdown showed fewer cell colonies compared to control group. (B) Staining 
intensity percentage of colony formation assay was analyzed by ImageJ software. BLCA cells 
with MIR31HG knockdown showed decreased staining intensity compared with control group. 
 
Migration was detected by a wound-healing assay. T24, UMUC3, and SCaBER 
cells with MIR31HG knockdown showed a larger open wound area compared 
with the control group after 12 h (Figure 22A). The difference in open wound 
area after 12 h was quantified by calculating the percentage of change in the 
open wound area (open wound area at 12 h - open wound area at 0 h). BLCA 
cells with MIR31HG knockdown showed fewer changes in open wound area 
compared with the control group (p = 0.0086 for T24, p = 0.2206 for UMUC3, p 
= 0.0182 for SCaBER, Figure 22B). 
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Figure 22. MIR31HG is required for migration of BLCA cells. (A) Wound healing assay was 
measured using cell culture inserts. T24, UMUC3, and SCaBER cells with MIR31HG 
knockdown showed more open wound area compared with control group after 12 h. (B) Open 
wound area was quantified by calculating the percentage of change in open wound area after 
12 h. BLCA cells with MIR31HG knockdown showed fewer changes in open wound area 
compared to the control group. 
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3.2.5 Splicing variants of MIR31HG regulate BLCA cell proliferation and 
migration with cell specificity 
To further evaluate the possible role of the transcripts MIR31HGΔE1 and 
MIR31HGΔE3 in BLCA, transcript-specific siRNAs were transfected into BLCA 
cells. T24, UMUC3, and SCaBER cells with MIR31HGΔE1 and MIR31HGΔE3 
knockdown by specific siRNA showed decreased cellular viability with cell 
specificity (Figure 23A-C). MIR31HGΔE1 knockdown showed significantly 
decreased absorbance in T24 (p = 0.0018, Figure 23A) and UMUC3 (p = 
0.0029, Figure 23B) cells after 72 h, and MIR31HGΔE3 knockdown resulted in 
a significant decrease in absorbance in SCaBER (p = 0.0346, Figure 23C) cells 
exclusively after 72 h.  
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Figure 23. Two splice variants of MIR31HG are required for proliferation of BLCA with 
cell specificity. (A-C) Cell viability was quantified using the MTS assay. MIR31HGΔE1 
knockdown showed a significant decrease in absorbance in T24 (p = 0.0018, A) and UMUC3 
(p = 0.0029, B) cells, and MIR31HGΔE3 knockdown showed a significant decrease in 
absorbance in SCaBER (p = 0.0346, C) cells after 72 h. 
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Colony formation was detected by culturing cells in 6-well plates and staining 
with crystal violet after 7 days. T24, UMUC3, and SCaBER cells with 
MIR31HGΔE1 and MIR31HGΔE3 knockdown by specific siRNA showed fewer 
cell colonies with cell specificity (Figure 24A). T24 and UMUC3 cells with 
MIR31HGΔE1 knockdown showed a significantly reduced staining intensity 
compared with control transfected cells. SCaBER cells with MIR31HGΔE3 
knockdown showed significantly decreased staining intensity (T24: p = 0.0017 
for MIR31HGΔE1, p = 0.0849 for MIR31HGΔE3; UMUC3: p = 0.0001 for 
MIR31HGΔE1, p = 0.7347 for MIR31HGΔE3; SCaBER: p = 0.1166 for 
MIR31HGΔE1, p = 0.0022 for MIR31HGΔE3; Figure 24B).  
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Figure 24. Two splice variants of MIR31HG are required for colony formation of BLCA 
with cell specificity. (A) Colony formation was detected by measuring cell staining after 7 days. 
T24, UMUC3, and SCaBER cells with MIR31HGΔE1 and MIR31HGΔE3 knockdown by specific 
siRNA showed fewer cell colonies with cell specificity. (B) Staining intensity percentage of 
colony formation assay was analyzed by ImageJ sofware. T24 and UMUC3 cells with 
MIR31HGΔE1 knockdown and SCaBER cells with MIR31HGΔE3 knockdown showed a 
significant decrease in staining intensity compared to the control group. 
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Migration was detected with a wound healing assay using cell culture inserts. 
T24, UMUC3, and SCaBER cells with MIR31HGΔE1 and MIR31HGΔE3 
knockdown by specific siRNA showed a larger open wound area compared with 
cell specificity after 12 h (Figure 25A). The difference in open wound area after 
12 h was quantified by calculating the percentage of change in open wound 
area (open wound area 12 h - open wound area 0 h). T24 and UMUC3 cells 
showed fewer changes in open wound area, both in the MIR31HGΔE1 and 
MIR31HGΔE3 knockdown groups. SCaBER cells showed fewer changes in the 
open wound area upon MIR31HGΔE3 knockdown (T24: p = 0.0305 for 
MIR31HGΔE1, p = 0.0105 for MIR31HGΔE3; UMUC3: p = 0.0006 for 
MIR31HGΔE1, p = 0.0165 for MIR31HGΔE3; SCaBER: p = 0.8160 for 
MIR31HGΔE1, p = 0.0079 for MIR31HGΔE3; Figure 25B). 
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Figure 25. Two splice variants of MIR31HG are required for migration of BLCA with cell 
specificity. (A) Wound healing assay was measured using cell culture inserts. T24, UMUC3, 
and SCaBER cells with MIR31HGΔE1 and MIR31HGΔE3 knockdown by specific siRNA 
showed a larger open wound area compared with cell specificity after 12 h. (B) Difference in 
open wound area was quantified by calculating the percentage of change in open wound area 
after 12 h. T24 and UMUC3 cells showed fewer changes in the open wound area, in both 
MIR31HGΔE1 and MIR31HGΔE3 knockdown groups. SCaBER cells showed fewer changes 
in the open wound area in the MIR31HGΔE3 knockdown group. 
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3.2.6 MIR31HG is associated with EGFR pathway 
To discover the potential mechanisms underlying the functions of MIR31HG, 
lncRNA-protein interactions were analyzed by lncPro. lncPro yields a score 
using amino acid and nucleotide sequences. This score can be used to 
measure the interaction between a pair of lncRNA and protein. The sequence 
of MIR31HG and protein sequences were obtained from the NCBI database 
(http://www.ncbi.nlm.nih.gov/). In total, nine isoforms of EGFR were predicted 
to interact with MIR31HG. MIR31HG was predicted as interactive with EGFR, 
phosphoinositide 3-kinase (PI3K) and receptor tyrosine-protein kinase erbB-2 
(HER2) protein (score above 50, Table 18). 
 
Table 18. Interaction scores of EGFR, PI3K HER2 protein and MIR31HG. 
Protein Score 
EGFR 72.4935 
EGFR isoform a 75.0794 
EGFR isoform b 93.4501 
EGFR isoform c 83.9972 
EGFR isoform d 93.8757 
EGFR isoform e 72.5006 
EGFR isoform f 75.7342 
EGFR isoform g 73.3893 
EGFR isoform h 82.7141 
EGFR isoform i 84.5429 
PI3K 75.5458 
HER2  isoform a 70.9194 
HER2  isoform b 82.7639 
HER2  isoform c 79.0902 
HER2  isoform d 69.6083 
HER2  isoform e 91.4699 
 
To further reveal the interaction with the coded gene, gene expression of EGFR 
was detected in MIR31HG knockdown cells. To narrow the differences in EGFR 
expression between cell lines, the 2−ΔΔCT values of expression data in T24, 
UMUC3 and SCaBER cells were normalized by the expression data in UROtsa. 
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Significantly higher expression of EGFR was observed in SCaBER cells with 
MIR31HG knockdown compared to the control group (p = 0.0367, Figure 20). 
No significant difference of expression was observed between T24 (p = 0.4086) 
and UMUC3 (p = 0.4734) cells with MIR31HG knockdown and control group 
(Figure 26). 
 
 
Figure 26. Expression of EGFR in BLCA cell lines with MIR31HG knockdown. EGFR 
expression was significantly higher in SCaBER cells with MIR31HG knockdown compared to 
negative siRNA group. Expression of EGFR showed no significant difference between T24 and 
UMUC3 cells with MIR31HG knockdown and negative siRNA group.  
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4 DISCUSSION 
Despite advances in surgical therapy, patients with MIBC after RC develop into 
local recurrence or metastases up to 40-50% of cases [96]. The clinical routine 
primarily uses the TNM stage and grading system to assess the prognosis, due 
to the tumor stage and lymphogenic metastasis having the greatest influence 
on the prognosis [97]. Nevertheless, these parameters are limited in predictive 
ability to the forecast. Therefore, it would be important to identify new 
biomarkers which enable more accurate prognostic risk and predictive 
stratification with regard to targeted therapies. In this study, the major aims are 
evaluating the RNA expression pattern of our interested genes ANLN, TLE2 
and MIR31HG with regard to molecular subtype, determining the correlated 
with the outcome of patients with MIBC and discovering the effects on biological 
function in BLCA. 
 
4.1 Regulation of ANLN, TLE2 and MIR31HG expression 
4.1.1 Expression of ANLN and TLE2 
In order to evaluate the translational benefit, gene expression was compared 
with molecular subtypes, targets, and relevant clinicopathologic parameters in 
multivariable analyses. As a key regulator of cytokinesis, it is not surprising that 
ANLN might play a critical role in carcinogenesis [98]. Previous research has 
established that knockdown of ANLN could significantly inhibit the proliferation 
of BLCA both in vitro and in vivo. Furthermore, knockdown of ANLN strongly 
suppressed the migration and invasion ability of J82 and 5637 bladder cancer 
cell lines [27]. Additionally, in upper urinary tract urothelial carcinoma, 
overexpression of ANLN in the nucleus is a poor prognostic factor, which was 
confirmed by data on protein levels, while low expression of ANLN in the 
cytoplasm is a poor prognosis marker [99]. In this study, ANLN was extensively 
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evaluated on mRNA level, showed the similar overexpression in MIBC tissues, 
which in accord with the protein level in nucleus of upper urinary tract urothelial 
carcinoma tissues [99]. However, the subcellular expression of ANLN in MIBC 
still need further investigation. 
In this thesis, ANLN expression was strongly correlated with cell proliferation 
markers including CDK1, RACGAP1, MKI67, and FOXM1. In urothelial 
carcinoma cell lines, these genes showed a consistently strong positive 
correlation with the expression of ANLN, which is highly expressed in ScaBER 
cells and expressed in low amounts in RT4 cells. In patient from the Mannheim 
cohort, a strong correlation of ANLN with RACGAP1, MKI67, and CDK1 was 
also found. These results indicate that ANLN could have a crucial role in tumor 
proliferation of MIBC. It is already known that the proliferation markers MKI67 
and RACGAP1 have a significant importance in BLCA [100, 101]. Previous 
research showed that mRNA expression of MKI67 is significantly correlated and 
associated with stage and grade in NMIBC [102]. Furthermore, the expression 
of RACGAP1 correlated significantly with the tumor stage in BLCA after RC, 
and RACGAP1 was strongly expressed in the early stages of NMIBC patient 
samples [87]. Additionally, FOXM1 has been shown to be overexpressed on 
the mRNA and protein levels in BLCA cells, and plays an important role in 
cisplatin resistance, outcome prediction, and risk stratification of patients with 
BLCA [103]. These results may indicate that ANLN and its correlated genes 
may supplement and optimize biomarker panels for molecular characterization 
of BLCA. 
In this study, TLE2 expression correlated with several Wnt pathway 
components, such as β-catenin (CTNNB1), TCF7, and LEF1 in the TCGA 
cohort. By analyzing the expression in the Mannheim cohort, it was also found 
that TLE2 was significantly correlated with CTNNB1. In addition, CTNNB1 is 
highly expressed in RT4 cells and expressed in lower amounts in ScaBER cells, 
which is similar to the expression pattern of TLE2. The activation of the Wnt/β-
catenin signaling pathway plays an important role in tumorigenesis and 
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development of various cancers including BLCA [33, 104, 105]. Gain-of-
function mutations in CTNNB1 are detected in numerous human cancers [106-
108]; therefore, it is necessary to explore the role of Wnt/β-catenin regulated 
genes in BLCA. Previous research has shown that TLE2 was significantly 
suppressed and the level of β-catenin protein was increased in esophageal 
tumor cells, both of which were modulated by NDRG1 overexpression [109]. 
These results may indicate that the differences of TLE2 expression in different 
BLCA cell lines may serve as trigger on activating Wnt/β-catenin signaling 
pathway. Interestingly, ANLN positively correlates with CTNNB1, while TLE2 
correlates inversely with CTNNB1, which was also observed in the Mannheim 
cohort. Although there is no direct correlation between ANLN and TLE2 in both 
cohorts, the involvement of ANLN and TLE2 underlying the Wnt/β-catenin 
signaling pathway was preliminarily revealed by this study. 
To reveal more details of ANLN and TLE2 expression in BLCA, the RNA-seq 
data of transcripts based on TCGA cohort were analyzed. Interestingly, the 
splice variants of ANLN and TLE2 showed different expression levels, with 
ANLN-201 (ENST00000265748.6), ANLN-202 (ENST00000396068.6), ANLN-
210 (ENST00000457743.1), ANLN-212 (ENST00000491782.1), TLE2-201 
(ENST00000262953.10), TLE2-202 (ENST00000426948.6), TLE2-204 
(ENST00000455444.6), and TLE2-215 (ENST00000590101.5) highly 
expressed compared with other transcripts. No existing study showed the 
correlation between clinical or histopathological features of MIBC and these 
splice variants. These findings indicate that differential expression patterns of 
ANLN and TLE2 splice variants might potentially have a practical usefulness, 
which needs further investigations. 
This study demonstrates that ANLN and TLE2 show a distinct subtype-specific 
overexpression in BLCA cell lines. ANLN showed overexpression in basal-like 
urothelial carcinoma cell lines and patients, while TLE2 showed significantly 
higher expression in luminal-like urothelial carcinoma cell lines and patients. 
Interestingly, for patients with MIBC in the whole TCGA cohort, ANLN and TLE2 
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harbored similar prognostic values for basal and luminal subtypes, respectively.  
Molecular classification has emerged as a promising research tool beyond 
histopathology to stratify cancer patients for personalized medicine [110]. 
Recent years have witnessed increasing interest and research into the 
molecular basis of BLCA [12]. Several studies subclassified both MIBC and 
NMIBC through RNA-seq-based data and identified distinct molecular subtypes 
that correlated with outcome and therapy response [111-113]. MIBC molecular 
subtypes, which are broadly grouped into basal and luminal subtypes, showed 
similarities to the molecular phenotypes of breast cancer [114]. It is believed 
that epithelial-to-mesenchymal transition (EMT) is a critical step in the 
progression of breast cancer, particularly the basal-like one [115]. The basal 
and EMT/claudin-low markers were highly expressed in the same subtype of 
patients with BLCA based on the TCGA database [13]. Due to the significant 
association with basal subtype of BLCA, it is suggested that ANLN could play 
a potential role in EMT in BLCA. Also, KRT5 is highly upregulated in basal and 
KRT20 in luminal subtype in BLCA [12]. qPCR-based molecular subtyping of 
BLCA by KRT5 and KRT20 mRNA expression is a method associated with the 
survival of patients with MIBC [116]. It is confirmed that KRT5 and KRT20 
showed significant association with ANLN and TLE2 in the Mannheim cohort. 
The differences of ANLN and TLE2 expression were not significant in the high 
KRT5 and KRT20 group maybe due the fact that only KRT5 and KRT20 were 
used for subtype association. 
 
4.1.2 Expression of MIR31HG and its splice variants 
In previous studies on multifarious tumors, MIR31HG showed a tissue-specific 
expression pattern. In breast cancer and non-small cell lung cancer (NSCLC) 
cells, MIR31HG expression was upregulated [67, 71]. In gastric cancer tissues 
and cell lines, MIR31HG was poorly expressed [69]. Another study showed that 
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MIR31HG level is substantially upregulated in oral carcinoma, significantly 
associated with poor clinical outcomes and representing an independent 
prognostic predictor [117]. In this study, lower MIR31HG transcript levels were 
found in luminal-like and mixed-type BLCA cell lines compared with a normal 
urothelium cell line. Accordingly, down-regulated MIR31HG expression was 
found in cancer tissues compared to normal tissues, which supports expression 
results measured by qPCR from a previous study [72]. However, the previous 
expression results were measured in stage- and type-mixed BLCA tissues, and 
in this study, MIR31HG was measured in MIBC and associated with multiple 
molecular subtype respectively. In contrast, MIR31HG was found to be highly 
expressed in cells lines and clinical tumor samples with the basal subtype 
compared to luminal and other subtypes, indicating that MIR31HG not only 
shows tissue specific, but also subtype-specific overexpression in MIBC. 
In contrast to a previous study, which reported that miR-31 and MIR31HG are 
down-regulated in triple-negative breast cancer (TNBC) cell lines of basal 
subtype [118], the present study shows that MIR31HG is highly expressed in 
the BLCA cell line of basal subtype and markedly correlates with the survival of 
patients with MIBC basal subtype. This might be due to different tumor entities 
and tissue specific expression of MIR31HG. In this study, two MIBC cohorts 
with multiple molecular subtypes were involved rather than single cell line, 
which may also lead to the dissimilar results. Further studies of BLCA preclinical 
models are needed for validation. For basal or squamous-like bladder cancer, 
molecular signatures were found based on clustering RNA-seq data, including 
EGFR [119]. EGFR is overexpressed in up to 74% of BLCA tissue specimens, 
and is amplified in squamous cell carcinomas (SCC) of the bladder [120]. To 
further investigate the potential relationship between MIR31HG and EGFR, a 
computational method called lncPro was applied to predict the associations 
within. All the nine isoforms of EGFR, as well as PI3K and HER2 protein, were 
predicted as interactive with MIR31HG. The positive interaction score 
suggested that MIR31HG might be involved in the EGFR/PI3K/AKT signaling 
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pathway. Furthermore, expression of EGFR was detected in three MIR31HG-
knockdown BLCA cell lines. In SCaBER cells, which shows the basal / 
squamous signature, expression of EGFR was reversely correlated with 
MIR31HG. According to another study on lung cancer, the protein expression 
of phosphorylated EGFR and PI3K were repressed in PC9 cells with MIR31HG 
siRNA transfected. By knocking down MIR31HG, reversal of gefitinib resistance 
was found by regulation of the EGFR/PI3K/AKT signaling pathway [121]. Taken 
together, these findings suggested that MIR31HG might potentially correlate 
with the EGFR pathway. 
A variety of mature RNAs are formed by different splicing during the 
transcription of a single gene. These mature RNAs are called the transcripts of 
the gene, and the process of generating different transcripts is called the 
alternative splicing process [122]. Alternative splicing affects the amino acid 
sequence of the translated protein by changing the coding sequence, or affects 
gene expression by changing the sequence of the untranslated region, thereby 
affecting biological functions [123, 124]. There are about 30,000 genes in the 
human genome, and about 95% of the genes can undergo alternative splicing 
[125]. As a post-transcriptional regulatory mechanism, alternative splicing 
greatly increases the complexity of genes and the diversity of proteomes [126]. 
In this study, it is noteworthy that two transcript variants of MIR31HG 
(MIR31HGΔE1 and MIR31HGΔE3) were identified and their expression was 
analyzed in BLCA cells and MIBC tissues. Besides the different expression 
levels in MIBC patient tissues, the two splice variants showed distinguished 
expression patterns in basal and luminal subtypes, respectively. MIR31HGΔE3 
showed high expression in the basal subtype, both in the TCGA cohort and the 
Mannheim cohort, which is also observed for the group with high KRT5 
expression. In contrast, MIR31HGΔE1 showed high expression in luminal 
subtype tumors in the Mannheim cohort, corresponding to tumors with a high 
KRT20 expression. To my knowledge, no existing data reported these two 
splice variants of MIR31HG. A previous study found that PVT1ΔE4, which is a 
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novel splice variant of lncRNA PVT1, was highly expressed in renal cell 
carcinoma, and could promote cell proliferation and invasion similar as the full-
length transcript [127]. Besides, expression of PVT1ΔE4 was even more 
abundant than its full-length sibling in renal cell carcinoma. These results may 
indicate that the full-length transcript and its splice variants could have 
coordinate or different expression and effect on tumor. 
 
4.2 ANLN, TLE2 and MIR31HG are prognostic markers for MIBC 
4.2.1 ANLN and TLE2 as prognostic markers for MIBC 
This study retrospectively evaluated the prognostic and clinical impact of ANLN 
and TLE2 gene expression and to validate these results in published datasets. 
Higher ANLN transcript levels were found to be associated with worse OS and 
DSS in the Mannheim cohort, which corresponds with results from previous 
studies of BLCA and upper urinary tract urothelial carcinoma [27, 99]. 
Supported results on 40 BLCA patients after RC or transuretheral resection 
showed that up-regulated expression of ANLN on mRNA level was correlated 
with poor DSS and DFS [27]. The study of upper urinary tract urothelial 
carcinoma with surgical intervention showed that, overexpression of ANLN in 
the nucleus and low expression in the cytoplasm on protein level was 
significantly associated with poor DSS and metastasis-free survival [99]. The 
subcellular localization of ANLN and correlation with outcome of MIBC patients 
still need further research. Together, these results indicate that ANLN, in 
addition to lymph node status, may be an independent predictor for DFS, and 
superior to the use of T stage and LVI as predictors. 
In contrast to ANLN, TLE2 was found to be dominantly expressed in patients 
with lower stages of BLCA. Patients with higher TLE2 expression had a more 
favorable OS and DFS, both in the whole-stage group and in the T2 subgroup. 
These results, together with univariable and multivariable Cox regression 
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analysis of the Mannheim and the TCGA cohort, suggest that TLE2 could serve 
as an independent risk factor for prognostic prediction of patients with BLCA. 
The most recent research about TLE2 showed an inhibition of replication and 
transcription in Kaposi’s sarcoma-associated herpesvirus [30]. To my 
knowledge, there is only very limited data about the role of TLE2 in cancer and 
no data specific to BLCA. Therefore, these findings are the first describing the 
role of TLE2 in BLCA. In adition, the Kaplan–Meier curves of ANLN and TLE2 
with OS and DSS showed separation at earlier time points, but convergence at 
later time points, between the high and low expression group in the TCGA 
cohort. It indicated that the predictive capabilities of ANLN and TLE2 expression 
might be stronger at earlier time points after RC. 
Until recently, effective targets following platinum-based chemotherapy were 
limited for patients with advanced urothelial carcinoma. The most promising 
option is immunotherapy with programmed cell death 1 (PD-1) / PD-L1 
checkpoint inhibitors, coupled with CTLA-4 antibodies [128, 129]. Apart from 
differences in expression thresholds for defining PD-L1 positivity, the validated 
biomarkers for optimal patient selection are still unrevealed [130]. In this study, 
expression of ANLN and TLE2 correlate with the therapeutic targets for BLCA 
as indicated in existing research and clinical trials. Notably, ANLN was 
positively and TLE2 was negatively correlated with PD-L1 in the TCGA cohort. 
TLE2 also showed a negative correlation with PD-1 and the key 
immunoregulator CTLA-4. These results suggest that ANLN and TLE2 could 
serve as potential biomarkers for response to immunotherapy and precise 
therapeutic management of MIBC. 
 
4.2.2 MIR31HG and its splice variants as prognostic markers for MIBC with 
basal subtype 
Similar as ANLN and TLE2, this study evaluated the correlation with survival 
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and expression of MIR31HG as well as its splice variants in MIBC cohorts. 
Higher MIR31HG transcript levels were found to be associated with worse OS 
and DFS in the basal subtype cohort, but not in the whole TCGA cohort. It is 
the first time to discover the prognostic value of MIR31HG in BLCA, or 
associated with subtypes of any other tumors. Two groups independently 
recognized the significance of a distinct basal MIBC subtype [131, 132]. 
According to classification of the TCGA, basal tumors were divided into two 
subsets that were largely distinguished by differential expression of biomarkers 
associated with EMT, which is a reversible developmental process by promoting 
invasion, metastasis, “stemness”, and drug resistance [111, 133]. The potential 
significance of the mesenchymal basal BLCA was identified using a “claudin-
low” gene expression signature in breast cancer [134]. A previous study 
reported that tumor suppressor microRNA-361 was de-repressed by MIR31HG 
in osteosarcoma cells, leading to cell growth and mesenchymal phenotype 
[135]. These results may indicate that high expression MIR31HG could be 
served as a surrogate marker of poor outcome defined by relative activation of 
EMT and sponge of tumor suppressor. The discovery that MIR31HG is highly 
expressed and significantly outcome-correlated in MIBC with basal subtype, 
has complemented the selection of MIBC markers. 
Furthermore, expression of MIR31HGΔE1 and MIR31HGΔE3 was significantly 
associated with OS and DFS in the Mannheim cohort, rather than the full-length 
transcript of MIR31HG. In the TCGA cohort, it was demonstrated that 
MIR31HGΔE3 expression was significantly associated with OS of the basal 
subtype group. These results, together with univariable and multivariable Cox 
regression analysis suggested that the alternative splice variants of MIR31HG 
may serve as potential biomarkers for certain molecular subtypes of MIBC, 
which could contribute to an individualized BLCA subclassification and therapy 
decision making. 
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4.3 MIR31HG and its splicing variants regulate BLCA tumorigenesis 
Due to its potential clinical relevance as a marker, the expression of MIR31HG 
and its underlying biological functions could be vital to the tumor. In this study, 
by knocking down MIR31HG expression using siRNA, diminished cell 
proliferation, colony formation, and migration were assessed in BLCA cell lines. 
This study is the first to highlight the function of MIR31HG in BLCA cells, which 
indicates that MIR31HG might serve as an oncogene in certain types of BLCA. 
With the in-depth study of MIR31HG, several downstream targets were found 
in present researches. For example, it is reported that overexpression of 
MIR31HG significantly decreased the expression of miR-575, enhanced the 
suppression of tumorigenicity 7 like (ST7L) in hepatocellular carcinoma (HCC). 
Thus, MIR31HG regulated ST7L expression through sponging miR-575, and 
acted as tumor suppressor in HCC [136]. Another published research showed 
that the level of MIR31HG in esophageal squamous cell carcinoma (ESCC) 
tissues was positively correlated with the expression of furin and matrix 
metalloproteinase 1 (MMP1). When MIR31HG was silenced, the expressions 
of furin and MMP1 in ESCC cells were significantly inhibited. These results 
suggest that the involvement of MIR31HG in invasion and migration of ESCC 
cell may be partly achieved through the furin / MMP1 pathway [137]. In a study 
in oral cancer, MIR31HG was identified as a hypoxia-inducible lncRNA and 
forms a complex with hypoxia-inducible factor-1 α (HIF-1α), thus as an adverse 
prognostic predictor for the cancer progression [117]. In addition, it was 
reported that MIR31HG could function as an oncogene that promotes 
pancreatic cancer progression, by acting as an endogenous sponge competing 
for miR-193b [70]. Similarly, it was shown that silencing of MIR31HG 
significantly inhibited NSCLC cell migration, invasion, and metastasis by 
attenuated sponging of miR-214 [71]. The various mechanisms of MIR31HG 
suggest that downstream pathways could be involved with other coding and 
non-coding RNAs, which requires further verification. 
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A number of studies have shown that alternative splicing plays an important 
role in tumors. For genes with multiple transcripts, certain transcripts or splice 
variants have specific functions in tumorigenesis and development. For 
example, the tight junction protein ZO-1 (TJP1) has multiple transcripts, among 
which the transcript retained by exon 23 (E23+) can inhibit the metastasis of 
colorectal cancer, while the transcript excised by exon 23 does not function in 
tumor metastasis [138]. As another example, CD44 is an important cell surface 
marker, and its alternative splicing are related to EMT, as well as its specific 
splice variants is related to the occurrence of EMT in tumor cells [139, 140]. 
There is also a report showed that different splice variants of the same gene 
can play diametrically opposite functions. VEGF165b and VEGF165 are two 
splice variants of vascular endothelial growth factor (VEGF), differing by only 
one exon. Yet their functions in tumors are diametrically opposite. VEGF165b, 
a protein translated by VEGF transcripts with variable exons, can inhibit tumor 
angiogenesis. While VEGF165, a protein generated by exon skip splice variant, 
promotes tumor angiogenesis [141]. As described for VEGF165b and 
VEGF165, which have diametrical functions, MIR31HG variants MIR31HGΔE1 
and MIR31HGΔE3 may potentially have different functions and involved in 
different pathways. 
In this study, similar to the full-length transcript, a series of functional 
experiments validated the corresponding roles of MIR31HG splice variants in 
certain types of BLCA cells. Knock down MIR31HGΔE3 resulted in reduced 
colony formation ability and cell viability solely in SCaBER cells, suggesting that 
exon-specific or transcript-specific mechanisms could be a new direction in 
studying basal-like BLCA. Recently, emerging data have demonstrated that 
RNA splice variants are associated with drug resistance in cancer. The 
expression of androgen receptor (AR) splicing variants in castration-resistant 
prostate cancer (CRPC) samples increased significantly. The most common AR 
splicing variants are AR-V7 and ARv567es [142, 143]. These AR splice mutants 
result from the alternative splicing of the AR precursor mRNA, and most of them 
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do not contain ligand binding regions, which are the targets of various AR 
antagonist drugs. Therefore, these AR splice variants are important factors for 
insensitive to AR antagonists of CRPC patients. Splice variants in V600E 
BRAF-mutant-positive malignant melanoma patients were shown to be 
associated with vemurafenib resistance, indicating that aberrant splicing could 
be a novel mechanism of acquired resistance [144]. Furthermore, interference 
of the pre-mRNA splicing modulators sufficiently inhibited formation of these 
splice variants, suggesting that splice variant-specific siRNAs may be proposed 
as a therapeutic strategy to overcome drug resistance [145]. 
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5 SUMMARY 
ANLN and TLE2 are associated with cancer patient survival and progression. 
The impact of their gene expression on survival of patients with MIBC treated 
with RC and subtype association has not yet been investigated. This study 
provides in silico and in vitro evidence supporting the prognostic potential of 
ANLN and TLE2 for patients with MIBC. In the Mannheim cohort, tumors with 
high ANLN expression were associated with lower OS and DSS, while high 
TLE2 expression was associated with a favorable OS. The TCGA cohort 
confirmed that high ANLN and low TLE2 expression was associated with 
shorter OS and DFS. In both cohorts, multivariable analyses showed ANLN and 
TLE2 expression as independent outcome predictors. Furthermore, ANLN was 
more highly expressed in cell lines and patients with the basal subtype, while 
TLE2 expression was higher in cell lines and patients with the luminal subtype. 
ANLN and TLE2 are promising biomarkers for individualized BLCA therapy 
including cancer subclassification and informed MIBC prognosis. These results 
indicate that developing ANLN and TLE2 as new biomarkers will help to further 
optimize personalized therapy for these patients. 
Growing evidence supports the pivotal role of lncRNAs in the regulation of 
cancer development and progression. Their expression patterns and biological 
function in MIBC remain elusive. In this study, a decreased expression of 
lncRNA MIR31HG was found in BLCA cells and tissues, except in the basal 
subtype. In vitro experiments revealed that knockdown of MIR31HG inhibits cell 
proliferation, colony formation and migration in BLCA. Survival analysis showed 
that high expression of MIR31HG was associated with poor OS and DFS in 
patients with MIBC of basal subtype. Two splice variants of MIR31HG lacking 
exon 1 (MIR31HGΔE1) and exon 3 (MIR31HGΔE3) were identified to have 
specific expression patterns in different subtypes of both MIBC cohorts. 
MIR31HGΔE3 was highly expressed in tumors with basal subtype. After 
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knockdown of splice variants of MIR31HG, cell proliferation and migration 
assays showed corresponding roles for the full-length transcript. A high 
expression of MIR31HGΔE1 and MIR31HGΔE3 was associated with worse OS 
and DFS in the Mannheim cohort. This study demonstrates that MIR31HG and 
its splice variants could serve as biomarkers for the classification and prognosis 
prediction of patients with MIBC. Taking together, this thesis provides new 
insights into studies for the molecular classification and relevance of RNA 
variants in MIBC. 
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